Статті в журналах з теми "342.240 858"
Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: 342.240 858.
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "342.240 858".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
1
Matus, Е. V., M. A. Kerzhentsev, A. P. Nikitin, S. A. Sozinov, and Z. R. Ismagilov. "Promising Directions in Chemical Processing of Methane from Coal Industry. Part 3. Catalytic Tests." Eurasian Chemico-Technological Journal 26, no. 1 (April 20, 2024): 3–14. http://dx.doi.org/10.18321/ectj1559.
Анотація:
For the processing of coal mine methane into hydrogen-containing gas, a catalytic process of methane tri-reforming (СH4 + O2 + CO2 + H2O) was proposed and its component reactions were studied – partial oxidation (СH4 + O2, POM), dry reforming (СH4 + CO2, DRM) and steam reforming (СH4 + H2O, SRM) of methane. Promoted nickel supported on aluminum oxide was used as a catalyst. Experiments were carried out by varying temperature (600–850 ºC), contact time (0.04–0.15 s), linear feed rate (40–240 cm/min) and composition of the reaction mixture (POM – СH4 : O2 : He = 1 : (0.5–0.7) : (3.3–3.4); DRM – СH4 : CO2 : He = 1 : (0.8–1.4) : (2.6–3.2); SRM – CH4 : H2O : He = 1 : (0.8–2.0) : (2.0–3.2)). Optimal reaction conditions were determined to ensure maximum efficiency of hydrogen production by reforming methane-containing mixtures of various compositions (temperature in the range of 800–850 ºC, contact time 0.15 s, linear feed rate 160 cm/min, molar ratio of CH4 : O2 = 1 : 0.5 for POM, CH4 : CO2 = 1 : 1 for DRM and CH4 : H2O = 1 : 1.1 for SRM). The degree of catalyst carbonization during the reactions was reduced (from 3 to 1.5% for POM, from 20.7 to 2.2% for DRM, and from 15.2 to 0.4% for SRM) due to an increase in the O/C molar ratio in the initial reaction mixture. Regulation of H2/CO molar ratio was achieved over a wide range (0.9–6.5). It has been shown that the hydrogen concentration in the resulting hydrogen-containing mixture is determined by the type of process and is equal to 30±5 vol.%.
2
Lapteva, N. K., and L. V. Mitkinykh. "Expansion of assortment of functional gingerbread products." Agricultural Science Euro-North-East 20, no. 4 (August 30, 2019): 334–42. http://dx.doi.org/10.30766/2072-9081.2019.20.4.334-342.
Анотація:
In order to expand the range of flour confectionary for healthy nutrition, documentation on new gingerbread products with increased food value was developed in 2017-2018. They are Prune gingerbread (kovrizhka) and gingerbread (pryanik) "Zabava", "Fantaziya", "Vdokhnovenie". The nutrition value of new gingerbread products is defined by the content of medium rye flour, sunflower oil, prunes, dried apricots, cocoa powder which enrich the products with many micronutrients necessary for a human body such as food fibers, mineral substances, vitamins, polyunsaturated fatty acids (PUFA). Prune gingerbread exceeds the production analog (Tula gingerbread) in the content of food fibers (3.6%), vitamin E (2.9 mg%) and vitamin B1 (0.11 mg%) by 2.25; 4.1 and 1.37 times, respectively. It also has more mineral substances (K, P, Ca, Mg, Fe) in comparison with the control - 2.0; 1.3; 1.4; 2.4; 1.4 times, respectively. Energy value of Prune gingerbread is 8.8% lower than that of the production analog (Tula gingerbread). In 100 grams of Prune gingerbread and gingerbreads "Zabava", "Fantaziya", "Vdokhnovenie" there are from 2.9 to 4.0 g of polyunsaturated linoleic acid that satisfy the minimum body need a day. Gingerbreads "Zabava", "Fantaziya", "Vdokhnovenie" exceed the production analog (gingerbreads “Festivalnye”) in the content of mineral substances (K, Ca, Mg, P, Fe) in total – by 46.4; 98.4; 45.0%, respectively; in food fibers – by 1.7-2.2 times; in vitamin E – by 1.9-2.0 times. New gingerbread products are functional as they contain 26.4-36.4% of average daily body need in PUFA and 29.0-37.0% of vitamin E. Gingerbreads 'Zabava' and 'Fantaziya' contain respectively 17.0 and 20.0% of average daily body need in food fibers and 15.7% – in iron.
3
Díaz-Mesa, E. M., M. P. García-Portilla, S. Al-Halabí, P. A. Sáiz, and J. Bobes. "Sexual dysfunction in patients with schizophrenia vs bipolar disorder." European Psychiatry 26, S2 (March 2011): 1542. http://dx.doi.org/10.1016/s0924-9338(11)73246-1.
Анотація:
IntroductionHealthy sexual functioning is an important part of the human experience, but there is a lack of studies regarding sexuality and sexual behavior in schizophrenia and bipolar disorder (García-Portilla, 2010).AimTo determine the differences on the sexual dysfunction profile between patients with schizophrenia and bipolar disorder.MethodNaturalistic, cross-sectional, multicentre, validation study. A total of 89 patients with schizophrenia (SQF) and 82 with bipolar disorder (BPD) were evaluated using the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14).ResultsSample description (SQF vs BPD): Mean age (SD) were 39.2 (11.0) vs 46.7 (10.9) (p < 0.001), men were 58.8% vs 41.2% (χ2 = 4.0, df. = 1, p < 0.05), 61.8% vs 38.2% were single (χ2 = 12.8, df. = 1, p < 0.001). Mean (SD) scores on CSFQ-14 scales were (SQF vs BPD): Pleasure 2.2 (1.0) vs 2.6 (1.0) (t = -2.2, p < 0.05), Sexual desire/frequency 5.3 (2.0) vs 5.9 (2.0) (t = -2.0, p < 0.05), Sexual desire/interest 5.7 (2.6) vs 6.9 (3.0) (t = -2.5, p < 0.05), Arousal/excitement 8.6 (3.1) vs 8.9 (3.4), Orgasm/completion 7.9 (3.2) vs 8.8 (3.2), Desire 11.1 (3.9) vs 12.9 (4.4) (t = -2.7, p < 0.05), Arousal 8.6 (3.1) vs 8.9 (3.4), Orgasm 7.9 (3.2) vs 8.8 (3.2) and Total 39.5 (9.7) vs 42.2 (11.0).ConclusionsPatients with schizophrenia have more difficulty to get pleasure and more problems in the phase of desire (frequency and interest) than the patients with bipolar disorder.
4
Casandjian, Jean-Marc, Jean Ballet, and Isabelle Grenier. "Assessing the Cosmic Infrared Background Monopole from Far-infrared to Millimeter Wavelengths." Astrophysical Journal 969, no. 2 (July 1, 2024): 112. http://dx.doi.org/10.3847/1538-4357/ad43df.
Анотація:
Abstract We measured the cosmic infrared background (CIB) monopole for the COBE Diffuse Infrared Background Experiment (DIRBE) and Planck High-Frequency Instrument (HFI) bands with an updated model for the Galactic dust emission. This model includes a dust excess recently observed in 25% of the sky mainly at high latitude compared to the prediction from N H I. We correlated observations from COBE/DIRBE and Planck-HFI with this model to extract the zero levels of the sky maps. We corrected for the isotropic interplanetary dust (IPD) emission and calibration gains and obtained CIB values of 1.4 ± 8.0, 24.5 ± 3.9, 15.4 ± 4.9, 6.8 ± 2.0, 3.2 ± 0.3, 1.5 ± 0.1, 0.40 ± 0.05, 0.11 ± 0.04, 0.014 ± 0.027, and 0.008 ± 0.012 nW m−2 sr−1 at 60, 100, 140, and 240 μm, and 857, 545, 353, 217, 143, and 100 GHz. We compared those numbers with previous direct CIB measurements and extragalactic source counts. We obtain CIB values lower than previous measurements for wavelengths above 140 μm. Below this value, the large uncertainty related to the IPD emission prevents a clear interpretation.
5
Burk, Kathleen. "The Marshall Plan: Filling in Some of the Blanks." Contemporary European History 10, no. 2 (July 2001): 267–94. http://dx.doi.org/10.1017/s0960777301002053.
Анотація:
Dominique Barjot, Rémi Baudouï and Danièle Voldman, eds., Les Reconstructions en Europe (1945–1949) (Paris: Editions Complexe, 1997), 342 pp., FF175, ISBN 2-870-27693-1. Matthias Kipping and Ove Bjarnar, eds., The Americanisation of European Business: The Marshall Plan and the Transfer of US Management Models (London: Routledge, 1998), 235 pp., £50.00, ISBN 0-415-17191-1. Jeffry M. Diefendorf, Axel Frohn and Hermann-Josef Rupieper, eds., American Policy and the Reconstruction of Western Germany, 1945–1955 (Cambridge: Cambridge University Press and the German Historical Institute, Washington, DC, 1993), 537 pp., £45.00, ISBN 0-521-43120-4. Hans-Herbert Holzamer and Marc Hoch, eds., Der Marshall-Plan: Geschichte und Zukunft (Landsberg/Lech: Olzog, 1997), 214 pp., ISBN 3-789-29349-0. Haus der Geschichte der Bundesrepublik Deutschland, 50 Jahre Marshall-Plan (Berlin: Argon Verlag, Berlin, 1997), 140 pp., ISBN 3-870-24387-2. Günter Bischof, Anton Pelinka and Dieter Stiefel, eds., The Marshall Plan in Austria (New Brunswick: Transaction Publishers, 2000), 588 pp., ISBN 0-765-80679-7. Michael Kennedy and Joseph Morrison Skelly, eds., Irish Foreign Policy 1919–1966: From Independence to Internationalism (Dublin: Four Courts Press, 2000), 352 pp., £39.50, ISBN 1-851-82404-9. Bernadette Whelan, Ireland and the Marshall Plan 1947–1957 (Dublin: Four Courts Press, 2000), 426 pp., £39.50, ISBN 1-851-82517-7. Charles Silva, Keep Them Strong, Keep them Friendly: Swedish–American Relations and the Pax Americana, 1948–1952 (Stockholm: Akademitryck AB, 1999), 376 pp., Kl.10.00, ISBN 9-171-53974-3. Chiarello Esposito, America's Feeble Weapon: Funding the Marshall Plan in France and Italy, 1948–1950 (Westport: Greenwood Press, 1994), 226 pp., £49.50, ISBN 0-313-29340-6. Fernando Guirao, Spain and the Reconstruction of Western Europe 1945–57 (London: Macmillan, 1998), 240 pp., ISBN 0-312-21291-7. Martin A. Schain, Marshall Plan Fifty Years After (Houndmills: Palgrave, 2001), £30.00, ISBN 0-333-92983-7 was published after this article went to press.
6
Zhemzhurov, M. L., G. M. Zhmura, I. E. Rubin, G. Z. Serebryany, N. M. Dneprovskaya, N. A. Tetereva, I. V. Rudenkov, and L. F. Babichev. "Predictive evaluation of changes in the volumes of radioactive waste to be deeply dispositioned in activated reactor structures in the process of their storage after the final shutdown of the Belarusian NPP power units." Proceedings of the National Academy of Sciences of Belarus, Physical-Technical Series 67, no. 3 (October 9, 2022): 332–44. http://dx.doi.org/10.29235/1561-8358-2022-67-3-332-344.
Анотація:
This paper presents the results of computational studies of the amount of solid high-level and long-lived intermediate level radioactive waste (HLW and ILW-LL) generated during neutron activation of structural materials adjacent to the core of the VVER-1200 reactor of the Belarusian NPP, depending on the time after the final shutdown of the reactor. The assessment of the volumes of HLW and ILW-LL of activation origin, formed over 60 years of operation of the VVER-1200 reactor, was carried out on the basis of computational studies of the induced activity of structural and shielding materials using reactor and Monte Carlo program codes (SERPENT 2, TVS-M, DYN3D, MCU- PD). As a result of calculation studies, it was established that the masses and volumes of activated materials, according to the levels of pollution related to HLW and ILW‑LL, within 10 years after the final shutdown of the VVER-1200 reactor of the Belarusian NPP will be 273 tons and 43 m3 , respectively. In the interval of 30–70 years, the masses and volumes of activated materials of these categories of RW will amount to 262 t and 33 m3 , respectively. From 100 years to 200 years, the masses and volumes of activated materials of these categories of RW will be 118 t and 15 m3 , respectively. Within 10 years after the reactor shutdown, isotopes 55Fe (2.7 years), 60Co (5.27 years), 63Ni (96 years) will make the main contribution to the value of the integral specific activity of the materials of the structures of the fence, shaft, surfacing, reactor vessel, block of protective tubes (BPT), the space under the core, thermal insulation; after 10 years – 63Ni. The main contribution to the value of the integral specific activity of materials of absorbing elements (PEL) with Dy2TiO5 during the entire period of storage will be made by 63Ni.
7
Kaul, Adam R., Loredana Salis, Mairead Nic Craith, and Stefan Handler. "Book Reviews." Anthropological Journal of European Cultures 18, no. 1 (March 1, 2009): 129–37. http://dx.doi.org/10.3167/ajec.2009.180108.
Анотація:
Coleman, S. and P. Collins (2007) (eds), Locating the Field, Space, Place and Context in Anthropology (Oxford: Berg), 256 pp., Pb: £19.99, ISBN-13: 978-1845204037.Screeton, P. (2008), Mars Bars and Mushy Peas: Urban Legend and the Cult of Celebrity (Loughborough: Heart of Albion), 184 pp., Pb: £14.95, ISBN-13: 978-1-905646-11-1.Smith, L, and A. Natsuko (2009) (eds), Intangible Heritage (London and New York: Routledge) 312 pp., Pb: £23.99, Hb: £70.00, ISBN-13: 978-0-415-47396-5.Tiesler, N. C. (2006), Muslime in Europa: Religion und Identitätspolitiken unter veränderten gesellschaftlichen Verhältnissen (Münster: LIT), 240 pp., Pb: €24.90, ISBN-13: 978-3-8258-9490-0.
8
Carlin, Jeffrey L., David J. Sand, Paul Price, Beth Willman, Ananthan Karunakaran, Kristine Spekkens, Eric F. Bell, et al. "FIRST RESULTS FROM THE MADCASH SURVEY: A FAINT DWARF GALAXY COMPANION TO THE LOW-MASS SPIRAL GALAXY NGC 2403 AT 3.2 MPC." Astrophysical Journal 828, no. 1 (August 25, 2016): L5. http://dx.doi.org/10.3847/2041-8205/828/1/l5.
9
Monteiro, Evoni Antunes, and Simey Thury Vieira Fisch. "Estrutura e padrão espacial das populações de Bactris setosa Mart e B. hatschbachii Noblick ex A. Hend (Arecaceae) em um gradiente altitudinal, Ubatuba (SP)." Biota Neotropica 5, no. 2 (2005): 111–17. http://dx.doi.org/10.1590/s1676-06032005000300007.
Анотація:
Foi feito um estudo da estrutura e padrão espacial das palmeiras Bactris setosa Mart. e B. hatschbachii Noblick ex A. Hend., em trechos de mata atlântica no município de Ubatuba-SP, para se avaliar as populações destas espécies no gradiente de altitude. Nestes locais foram realizadas amostragens em seis altitudes (0 m - nível do mar, 100, 200, 400, 600, 850 m) em parcelas circulares de 100 m², onde todos os indivíduos das duas espécies foram medidos. As populações foram divididas em cinco classes de tamanhos: classe 1 (acaule); classe 2 (1 a 50 cm); classe 3 (51 a 100 cm); classe 4 (101 a 200 cm); classe 5 (> 200 cm). Ambas populações apresentaram predominância de indivíduos na classe seguinte a de plântulas. Ao nível do mar, as duas espécies foram abundantes (B. hatschbachii, 472 ind/ha e B. setosa, 312 ind/ha) e na encosta a espécie B. hatschbachii foi mais populosa a 400 m de altitude (400 ind/ha) e B. setosa a 600 m (148 ind/ha), a 850 m as duas espécies não foram amostradas. O índice de Morisita (Id) indicou um padrão espacial agregado para as populações de ambas espécies. O padrão populacional apresentado demonstrou que estas palmeiras são restritas a ambientes favoráveis.
10
Lynch, Christel, Asa Gudrun Kristjansdottir, Saskia J. te Velde, Nanna Lien, Eva Roos, Inga Thorsdottir, Michael Krawinkel, et al. "Fruit and vegetable consumption in a sample of 11-year-old children in ten European countries – the PRO GREENS cross-sectional survey." Public Health Nutrition 17, no. 11 (July 15, 2014): 2436–44. http://dx.doi.org/10.1017/s1368980014001347.
Анотація:
AbstractObjectiveTo describe fruit and vegetable intake of 11-year-old children in ten European countries and compare it with current dietary guidelines.DesignCross-sectional survey. Intake was assessed using a previously validated questionnaire containing a pre-coded 24 h recall and an FFQ which were completed in the classroom. Portion sizes were calculated using a standardized protocol.SettingSurveys were performed in schools regionally selected in eight countries and nationally representative in two countries.SubjectsA total of 8158 children from 236 schools across Europe participating in the PRO GREENS project.ResultsThe total mean consumption of fruit and vegetables was between 220 and 345 g/d in the ten participating countries. Mean intakes did not reach the WHO population goal of ≥400 g/d in any of the participating countries. Girls had a significantly higher intake of total fruit and vegetables than boys in five of the countries (Sweden, Finland, Iceland, Bulgaria and Slovenia). Mean total fruit intake ranged between 114 and 240 g/d and vegetable intake between 73 and 141 g/d. When using the level ≥400 g/d as a cut-off, only 23·5 % (13·8–37·0 %) of the studied children, depending on country and gender, met the WHO recommendation (fruit juice excluded).ConclusionsFruit and vegetable consumption was below recommended levels among the schoolchildren in all countries and vegetable intake was lower than fruit intake. The survey shows that there is a need for promotional activities to improve fruit and vegetable consumption in this age group.
11
Engl, Werner, Lisa Patrone, Dyck-Jones Jacqueline, Srilatha D. Tangada, and Brigitt E. Abbuehl. "An Evaluation of Safety with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of 243 Patients with Hemophilia a." Blood 128, no. 22 (December 2, 2016): 3801. http://dx.doi.org/10.1182/blood.v128.22.3801.3801.
Анотація:
Abstract BAX 855 is an extended half-life, pegylated full-length recombinant factor VIII (PEG-rFVIII) built on ADVATE and is approved for prophylaxis and the treatment of bleeding in hemophilia A. Safety data from 7 clinical studies were integrated to evaluate single, short-term, and long-term exposure with BAX 855. These clinical trials included the following patients: previously treated adult, adolescent, and pediatric patients (PTPs) and previously untreated patients (PUPs). Immunogenicity, adverse events (AEs), and clinical laboratory parameters were assessed during prophylaxis, treatment of bleeding, perioperative management, and PK evaluations. Of 243 patients, the mean ±SD (range) age was 23.4 ±15.84 (0-61) years, there was 1 female; 74.9% of patients were White, 21.4% were Asian, and 2.5% were Black. Overall, 97 million IUs of BAX 855 were infused, resulting in a median (Q1; Q3) of 111 (73-196) exposure days (EDs) per patient, which ranged from 1 to 322 EDs. No patient developed inhibitory antibodies to FVIII (≥0.6BU) at any time. The 95% confidence intervals for developing inhibitory antibodies based on exposure are as follows: 0-0.19 for 191 PTPs with ≥50 EDs, 0-0.027 for 135 patients with ≥100 EDs, 0-0.37 for 98 patients with ≥150 EDs, and 0-0.68 for 52 patients with ≥200 EDs. At the time of the last blood sample analyzed, no patient had any antibodies to CHO proteins or persistent binding antibodies to FVIII, PEG-FVIII, or PEG. Binding antibodies were either pre-existing (28 patients) or transient (13 patients). No conclusion can be drawn as yet for 5 patients who developed binding antibodies shortly before or at the data cut-off for the analysis. The presence of binding antibodies could not be correlated to an altered PK or impaired efficacy. The only AE considered related to BAX 855 occurring in ≥1% of patients was headache; other related AEs (nausea; diarrhea, flushing, rash, and hypersensitivity) were observed in <1% of patients. No SAEs related to the use of BAX 855 were reported. One PUP discontinued due to a treatment-related AE: a mild, non-serious AE of hypersensitivity (a rash), which resolved. In total, 819 AEs were reported in 182/243 subjects administered ≥1 BAX 855 infusion. The overall rate of AEs/infusion was 2.7% (819 AEs/30,865 infusions), for non-serious AEs 2.5% (773 AEs/30,865), and for serious AEs 0.1% (46/30,865). No trends were observed in laboratory parameters or in vital signs. This safety update for BAX 855 confirms that the safety profile of BAX 855 is consistent with the safety profile of ADVATE. Overall, short- and long-term treatment with BAX 855 was safe and well tolerated in 243 pediatric, adolescent and adult subjects with severe hemophilia A from 3 completed and 4 ongoing studies. As experience with BAX 855 grows, this integrated safety update continues to confirm the safe use of BAX 855 for prophylaxis, the treatment of bleeding episodes, and perioperative management. Disclosures Engl: Shire, formerly Baxalta and Baxter: Employment, Equity Ownership. Patrone:Shire, formerly Baxalta and Baxter: Employment, Equity Ownership. Jacqueline:Baxalta US Inc., now part of Shire: Employment, Equity Ownership. Tangada:Baxalta US Inc., now part of Shire: Employment, Equity Ownership. Abbuehl:Shire, formerly Baxalta and Baxter: Employment, Equity Ownership.
12
Soelberg-Sorensen, Per, Fernando Dangond, Christine Hicking, and Gavin Giovannoni. "WED 182 Cladribine tablets effects on lymphocytes in ms patients." Journal of Neurology, Neurosurgery & Psychiatry 89, no. 10 (September 13, 2018): A25.1—A25. http://dx.doi.org/10.1136/jnnp-2018-abn.87.
Анотація:
BackgroundLymphopenia is expected from the mechanism of action of cladribine tablets 3.5 mg/kg (CT3.5)ObjectiveInvestigate absolute lymphocyte counts (ALC; 312 weeks) and subsets (240 weeks) in RRMS patients receiving 2 annual courses of CT3.5.MethodsPooled data from patients randomised to CT3.5 over 2 years in CLARITY/CLARITY-Extension inclusive of the PREMIERE registry (n=685).ResultsBaseline: median ALC=1.86 × 109/L. Year-1: ALC reached nadir at 9 weeks post-treatment with CT3.5 (1.00 × 109/L). Year-2: ALC reached nadir at Week-55 (0.81 × 109/L), then recovered to the normal range (≥1.00 × 109/L; Week-96). ALC was in normal range in 75% of patients by Week-144. Baseline median CD4+ were 851 cells/µL. Nadirs occurred at Week-16 (385 cells/µL) in Year-1 and at Week-60 (292 cells/µL) in Year-2; values increased after nadirs and regained threshold (350 cells/µL, ~Week-120). Baseline median CD8+ were 378 cells/µL. Nadirs occurred at Week-16 (239 cells/µL; Year 1) and Week-72 (232 cells/µL; Year 2). CD8+ recovered quickly after treatment and remained above 200 cells/µL at all times. Baseline median CD19+ were 205 cells/µL. Nadirs occurred at Week-9 (18 cells/µL; Year-1) and Week-52 (31 cells/µL; Year-2). CD19+ then reached threshold of 100 cells/µL by the end of Year-2.ConclusionLymphocyte recovery begins soon after CT3.5. ALC, CD19+ B and CD4+ T cells; reached threshold by 7.5, 12 and 18 months. CD8+ cells remained above threshold.Disclaimerhttp://medpub-poster.merckgroup.com/ABN2018DISC_LongLymph.pdf
13
Wainberg, Zev A., Kai-Keen Shiu, Fernando Rivera, Louise C. Medley, Morteza Aghmesheh, Richard Francis Dunne, Rajarshi Roy, et al. "First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type." Journal of Clinical Oncology 42, no. 3_suppl (January 20, 2024): 345. http://dx.doi.org/10.1200/jco.2024.42.3_suppl.345.
Анотація:
345 Background: First-line (1L) treatment of GEJC and EAC is similar to that for gastric adenocarcinomas, based on evidence from 2 large phase 3 gastric and esophageal cancer trials. The phase 3 KEYNOTE-590 trial (NCT03189719) showed 1L pembro + chemo significantly improved OS and PFS in pts with esophageal cancer. The phase 3 KEYNOTE-859 trial (NCT03675737) showed 1L pembro + chemo significantly improved OS, PFS, and ORR in pts with HER2-negative gastric cancer or GEJC. This post hoc, exploratory analysis was conducted to examine the efficacy of 1L pembro + chemo in the GEJC and EAC subgroups of KEYNOTE-590 and the GEJ subgroup of KEYNOTE-859. Methods: Pts with untreated advanced EAC or Siewert type 1 adenocarcinoma of the GEJ (KEYNOTE-590) or HER2-negative GEJ adenocarcinoma (KEYNOTE-859), measurable disease per RECIST v1.1, and ECOG PS 0 or 1 were evaluated. In both studies, pts were randomly assigned 1:1 to receive pembro 200 mg IV or pbo every 3 wk (Q3W) for ≤35 cycles, each with chemo (5-fluorouracil + cisplatin [FP] in KEYNOTE-590; FP or capecitabine + oxaliplatin in KEYNOTE-859). Efficacy end points for this analysis were OS and PFS (per RECIST v1.1 by blinded independent central review) by tumor subtype. Database cutoff was July 2, 2020, for KEYNOTE-590 and July 1, 2022, for KEYNOTE-859. Results: Overall, 201 pts from KEYNOTE-590 (n=99 pembro + chemo; n=102 pbo + chemo) with GEJC or EAC and 334 pts from KEYNOTE-859 (n=149 pembro + chemo; n=185 pbo + chemo) with GEJC were included. In KEYNOTE-590, 91 pts had GEJC only (n=41 pembro + chemo; n=50 pbo + chemo) and 169 (n=82 pembro + chemo; n=87 pbo + chemo) had GEJC + EAC + CPS ≥1. In KEYNOTE-859, 287 pts (n=123 pembro + chemo; n=164 pbo + chemo) had GEJC + CPS ≥1. Demographic and baseline characteristics were well balanced. Median time from randomization to database cutoff for pts with GEJC and EAC was 23.5 mo (range, 15.3-33.6) in KEYNOTE-590 and 25.8 mo (range, 12.4-43.0) in KEYNOTE-859. Efficacy outcomes by tumor type are shown in the Table. Conclusions: Consistent with results from the ITT populations of KEYNOTE-590 and KEYNOTE-859, 1L pembro + chemo provided clinically meaningful improvement in OS and PFS vs chemo in pts with untreated advanced GEJC and EAC. These data support the use of 1L pembro + chemo for pts with advanced GEJC and EAC. Clinical trial information: NCT03189719 and NCT03675737 . [Table: see text]
14
Tankel, James, Nabeel Ahmed, Thierry Alcindor, Jamil Asselah, Petr Kavan, Frederic Lemay, Dominique A. Frechette, et al. "Docetaxel-based triplet neoadjuvant therapy for esophageal adenocarcinoma: A comprehensive analysis of outcomes spanning over a decade." Journal of Clinical Oncology 41, no. 4_suppl (February 1, 2023): 332. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.332.
Анотація:
332 Background: Docetaxel-based therapy is currently the most effective neoadjuvant regimen for locally advanced gastroesophageal adenocarcinoma. However, prior trials were primarily designed to target gastric cancer. As survival associated with taxane-based chemotherapy in esophageal adenocarcinoma (EAC) is less well described, we sought to review our experience with docetaxel based therapy as a neoadjuvant approach for EAC. Methods: A single centre retrospective review of a prospectively maintained upper GI cancer surgical database was performed (2008-2021). Patients with EAC undergoing curative intent neoadjuvant therapy with two similar docetaxel-based regimens (DCF - Docetaxel/Cisplatin/5FU or FLOT - 5FU, Leucovorin, Oxaliplatin, and Docetaxel) followed by en-bloc resection were included. Gastric/EGJ type III tumors were excluded. Clinicopathological data and overall survival (OS) were recorded and stratified by chemotherapy type (DCF vs FLOT). Data are presented as median (+/-SD). Mann-Whitney U tests for continuous or Fischer exact test for categorical variables determined significance. Kaplan-Meier curves compared OS. Results: 225 EAC patients were identified: Age 64.2 (±10.3) and tumor location was Esophageal/EGJ I/EGJ II (106/33/86). Clinical stage was cT3-4 in 201/225 (89.3%) and most were cN+ (200/225: 88.9%). There were 121 (53.7%) treated with neoadjuvant DCF whilst 104 (46.3%) received FLOT. All pre-op cycles were completed in 181 (80.4%) and did not differ between DCF and FLOT (81.8% vs 78.8% - NS). Operative procedure included Ivor Lewis in 188 (83.5%), left thoraco-abdominal esophagectomy in 20 (8.8%), and McKeown in 17 (7.5%) and also did not differ between DCF and FLOT. In terms of pathologic outcomes, the median lymph node yield was 35 (±16) of which 3.6±5.8 were positive). There was no difference when comparing between regimens. There were 134 (59.6%) patients ypN1-3 (DCF=76(62.8%) vs FLOT=58(55.8%)- NS). An R0 resection was achieved in 210 (93%) patients (DCF=92.6% vs FLOT=94.2%- NS). Complete pathological response (no residual cancer) was found in 21 patients (9.3%) (DCF=14(11.6%) vs FLOT=7(6.7%) – NS). At follow up of 41(±36) months (DCF= 52±41 vs FLOT=27±23 - p<0.001) OS (KM curve Fig 1) at 1, 3 and 5 years for the entire cohort was 91.4%, 62.8%, and 55.7%, with no difference between DCF (92.3%/68.8%/59.5%) and FLOT (89.8%/54.5%/51.7% - NS). Conclusions: This retrospective review, the largest yet reported, demonstrates that these similar docetaxel-based neoadjuvant chemotherapy regimens are highly effective for patients with locally advanced esophageal adenocarcinoma.
15
Gushchina, N. V., V. V. Voronin, N. V. Proskurnina, V. V. Bobrovskii, K. V. Shalomov, and V. V. Ovchinnikov. "The effect of ion irradiation (Ar+, E = 15-20 keV) on the microstructure of the deformed Ni - 13.9 Wt.% W alloy." Izvestiya vysshikh uchebnykh zavedenii. Fizika, no. 1 (2022): 112–18. http://dx.doi.org/10.17223/00213411/65/1/112.
Анотація:
Using X-ray diffraction analysis, the effect of Ar+ ions with an energy of 15-20 keV (at ion current densities of 100-300 μA/cm2) on the microstructure, the level of internal microstresses and the texture of cold rolled ribbons of alloy Ni-13.9 wt.% W was studied. It was found that short-term irradiation of 80 μm thick ribbons with a fluence of 3.1·1016 cm-2 (for 50 s) at temperatures T ≤ 370°C and T = 630°C leads to a decrease in microstresses in their entire volume, but at the same time the original texture is retained. With an increase in the fluence to 9.7·1017 cm-2 at T = 630°C, the texture also changes from (220) to (200). Changes in microstresses and texture on the irradiated and unirradiated sides of 80-μm-thick ribbons are comparable to each other, despite the fact that the projective range of Ar+ ions with an energy of 15-20 keV in the alloy is only ~7 nm. It is known that annealing in an oven (700°C, 30 min) of such ribbons does not lead to their recrystallization. At 850°C, microstresses are relieved and the texture drastically changed from (220) to (200) both as a result of annealing in a furnace (15 s) and as a result of irradiation with a fluence of 3.2·1016 cm-2 for 17 s, but the effect removal of stresses in the course of furnace annealing is 3 times lower than in the course of irradiation. Thus, the following facts have been established: 1) the occurrence of recrystallization processes in the alloy under study during irradiation at a temperature lower than the temperature of the onset of thermally activated recrystallization and 2) a higher rate of microstresses drop (and to lower values) in the course of irradiation than during furnace annealing. This indicates a significant role of nanoscale radiation-dynamic effects at the cascade-forming irradiation of metastable media.
16
Beyers, Julie Miethke, Diane R. Follingstad, Heather D. Breiter, Jeanne Marecek, and Jeanette N. Cleveland. "Reviews." Psychology of Women Quarterly 18, no. 4 (December 1994): 643–45. http://dx.doi.org/10.1111/j.1471-6402.1994.tb01052.x.
Анотація:
Career Counseling for Women, W. Bruce Walsh and Samuel H. Osipow (Eds.). Hillsdale, NJ: Erlbaum, 1994. 385 pp. $34.50 (paper). ISBN 0-8058-1401–9. It Could Happen to Anyone: Why Battered Women Stay, Ola W. Barnett and Alyce D. LaViolette. Thousand Oaks, CA: Sage, 1993. 184 pp. $38.00. ISBN: 0-8039-5310–0. Empowering and Healing the Battered Woman, Mary Ann Dutton. New York: Springer, 1992. 202 pp. $28.95. ISBN: 0-8261-7130–3. Breaking Destructive Patterns: Multiple Strategies for Treating Partner Abuse, Janet A. Geller. New York: Free Press, 1992. 182 pp. $27.95. ISBN: 0-02-911605–8. Against Therapy, Jeffrey Moussaieff Masson. Monroe, ME: Common Courage Press, 1988/1994. 340 pp. $15.95. ISBN 1-56751-022–1. Changing Our Minds: Lesbian Feminism and Psychology, Celia Kitzinger and Rachel Perkins. New York: New York University Press, 1993. 216 pp. $14.95. ISBN: 0-8147-4646–2. Cultures of Organizations. Three Perspectives, Joanne Martin. New York: Oxford University Press, 1992. 240 pp. $35.00. ISBN 0-19-507163–8.
17
RAHMAN, M., A. AHMAD, and S. SHOMA. "Decline in epidemic of multidrug resistant Salmonella Typhi is not associated with increased incidence of antibiotic-susceptible strain in Bangladesh." Epidemiology and Infection 129, no. 1 (August 2002): 29–34. http://dx.doi.org/10.1017/s0950268802007203.
Анотація:
Since 1987, multidrug resistant (MDR) strains of Salmonella Typhi, resistant simultaneously to ampicillin, chloramphenicol and trimethoprim-sulfamethoxazole, have caused epidemics of severe typhoid fever in Asia and Africa. A retrospective analysis of blood culture results (1989–96) in a Diarrhoea Treatment Centre in Dhaka, Bangladesh detected MDR strains in 0.3% (8 of 2793) of samples in 1990. The isolation rate peaked to 3.2% (240 of 7501) in 1994 (P<0.01) and decreased to 1.8% (165 of 9348) in 1995 and further to 1.0% (82 of 8587) in 1996 (P<0.01 compared to 1994) indicating the emergence and decline of MDR typhoid epidemic. Ten of 15 MDR strains tested had a 176 kb conjugative R plasmid that mediates resistance to ampicillin, chloramphenicol and trimethoprim-sulfamethoxazole to Escherichia coli K12. Unlike MDR strains, the isolation rate (∼3.3%) of susceptible S. Typhi remained remarkably unchanged during the study. The significant decrease in isolation of MDR strains suggests that cheaper and effective first-line antibiotics may re-emerge as drugs of choice for the treatment of typhoid fever in Bangladesh.
18
Calles, Antonio, Alejandro Navarro, Bernard Doger, Maria J. de Miguel, Rosa Maria Alvarez Alvarez, Victor Moreno, Jorge Ramón, et al. "A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 8581. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.8581.
Анотація:
8581 Background: L is a novel anticancer agent that inhibits trans-activated transcription and modulates the tumor microenvironment. L is approved by the FDA for metastatic SCLC patients (pts) with progressive disease (PD) on or after platinum-based chemotherapy (CT). The LUPER study is assessing the safety, tolerability, and preliminary efficacy of L+P as second-line regimen for SCLC pts after failure of platinum-based CT. Phase 1 data are presented here. Methods: In this phase 1/2 trial (NCT04358237), adult pts with histologically confirmed SCLC, PD to a previous CT-containing regimen (≥4 weeks before study initiation), no prior exposure to immunotherapy, ECOG PS of 0-1, and measurable disease as per RECIST 1.1 are eligible. Pts with treated, stable, and asymptomatic brain metastases (BMs) are allowed. A 3+3 dose-escalation was done to determine the recommended phase 2 dose (RP2D) of L+P. L was dosed at 2.4 mg/m2 and 3.2 mg/m2 IV Q3W in the dose level (DL)1 and 2, respectively, in combination with fixed dose of P (200 mg IV Q3W). The RP2D was the highest DL at which 0/3 pts or ≤1/6 pts experienced dose-limiting toxicities (DLTs) during the first cycle. Treatment was administered until PD, unacceptable toxicity, or consent withdrawal. Secondary endpoints include safety as per CTCAE 5.0, preliminary efficacy, and pharmacokinetics. Results: Thirteen pts were enrolled across 3 hospitals in Spain (DL1, n = 7; DL2, n = 6). Median age was 66 (range 43–78) years, 46.2% were female, 61.5% had ECOG PS of 1, 38.5% had platinum-free interval < 90 days, 30.8% had LDH > upper normal limit, and 15.4% had BMs. One DLT (G3 asthenia) and one G4 neutropenia lasting > 3 days (controlled with G-CSF prophylaxis upon C2, without requiring dose delay or modification) occurred in the DL1. No DLT were reported in the DL2. The RP2D was identified as 3.2 mg/m2 L and 200 mg P IV Q3W. At data cutoff (Jan 21, 2022), 5 (38.4%) pts remained on treatment (1 pt in DL1 discontinued due to COVID-19 in cycle 1). Median duration of treatment was 2.1 (0–11.8) months, 5 (38.5%) pts had ≥8 cycles, and median relative dose intensity of L and P were 91.1% and 95.7%, respectively. Immune-related AEs (G2 pneumonitis; G3 ALT increased) led to P discontinuation in 2 (15.4%) pts. Responses were shown in both DLs, with ORR of 30.8% (1 confirmed complete response and 3 partial responses); 3 pts had stable disease (SD; including 1 patient with SD > 12 weeks) and 5 (38.5%) pts experienced PD. Conclusions: This is the first report to demonstrate a manageable safety profile and preliminary efficacy of second-line L+P for relapsed SCLC pts. This combination warrants further confirmation in the ongoing expansion phase 2. Clinical trial information: NCT04358237.
19
Fokam, Joseph, Desire Takou, Maria Santoro, Armanda Nangmo, Samuel M. Sosso, Georges Teto, Vittorio Colizzi, Carlo-Federico Perno, and Alexis Ndjolo. "PO 8580 TREATMENT RESPONSE AMONG CAMEROONIAN ADOLESCENTS RECEIVING ANTIRETROVIRAL THERAPY IN URBAN AND RURAL SETTINGS: PRELIMINARY FINDINGS FROM THE READY STUDY." BMJ Global Health 4, Suppl 3 (April 2019): A58.1—A58. http://dx.doi.org/10.1136/bmjgh-2019-edc.152.
Анотація:
BackgroundTransitioning from paediatric to adult healthcare requires successful antiretroviral treatment (ART) for adolescents living with HIV (ADLHIV). Implementing such a policy implies monitoring ART response and selecting for therapeutic options for ADLHIV in resource-limited settings (RLS) like Cameroon.MethodsThe Ready study (EDCTP-CDF-1027) is conducted amongst ART-experienced ADLHIV (10–19 years old) in the Centre region, Cameroon. WHO-clinical staging, CD4-counts and viraemia were determined; in case of virological failure [VF] (viraemia ≥1000 copies/ml), HIV drug resistance (HIVDR) and subtyping were performed, and p<0.05 considered significant.ResultsOut of 279 ADLHIV (212 urban vs 67 rural), the gender distribution was similar (54.5% female); median age was higher in urban (15 [IQR: 13–17] years) compared to rural (13 [IQR: 11–17] years), as well as the median duration on ART (7 [IQR: 3–10] years compared to 4 [IQR: 2–7] years, respectively); and the majority was on first-line ART (79.4% [162/204] urban vs 98.5% [66/67] rural, p<0.0004). Following treatment response, clinical failure (WHO-stage 3/4) was similarly low in both urban (5.7% [12/210]) and rural (4.5% [3/67]), p=0.938; CD4 increased similarly (p=0.298) from ART-initiation (370 cells/mm3[urban] vs 332 cells/mm3[rural]) to 6 years after initiation (938 cells/mm3[urban] vs 548 cells/mm3[rural]) and rate of immunodeficiency (<500 CD4 cells/mm3) was 41.0% (87/208) in urban vs 47.5% (29/61) in rural, p=0.428. VF was 43.2% (41/95) in urban vs 60.9% (14/23) in rural, p=0.126. Among nine (9) sequences available from those experiencing VF, overall HIVDR was found in 88.8%, with 77.7% NNRTI, 55.6% NRTI and 22.2% PI/r. All were HIV-1 group M, with 55.6% CRF02_AG, 22.0% F1 and 22.4% others.ConclusionADLHIV appear clinically asymptomatic, with considerable immune recovery overtime. Despite differences in ART duration between urban and rural settings, VF was similarly high, associated with HIVDR mainly to NNRTI-based regimens. Thus, NNRTI-sparing regimens might be highly convenient when transitioning ADLHIV to adult ART-regimens in RLS like Cameroon.
20
Wang, Zhuzhu, Jiayuan Zhuang, Qiaoxian Zhang, Xiaolan Lai, Qixi Liu, Baoyuan Xie, and Qinmei Tang. "Recognition of Elder Abuse by Chinese Nursing Undergraduates: Evaluation by the Caregiving Scenario Questionnaire." Innovation in Aging 4, Supplement_1 (December 1, 2020): 16. http://dx.doi.org/10.1093/geroni/igaa057.052.
Анотація:
Abstract This study aimed to evaluate the recognition of elder abuse (EA) among nursing undergraduates in China and determine whether recognition is related to sociodemographic factors and education. We conducted a cross-sectional study with stratified random sampling, using the Caregiving Scenario Questionnaire of Chinese version (CSQ-CV). Questionnaires were disseminated to 343 nursing undergraduates ranged from 1st to 4th year at Fujian Medical University, China. The content validity of CSQ-CV is 0.97. 340 students (99.1%) effectively responded. 223(65.6%) of them identified trapping someone in an armchair; 108(31.8%) locking someone alone; and 3(0.9%) accepting someone was not clean as abusive. The majority correctly identified four out of five non-abusive (NA) items, while 210(61.8%) incorrectly identified camouflaging the door to prevent wondering outdoors. With respect to potential-abusive (PA) items, less than half of the students made right judgements. Only 30(8.8%) correctly identified not taking her to family gatherings; 46(13.5%) telling her only having breakfast after bathing; and 50(14.7%) hiding tablets in someone’s cereal or tea. Mann-Whitney and Kruskal-Wallis tests indicated no significance related to correct recognition of the three abusive items with sociodemographic factors and education. The students who were female, caring older adults at home or had detected EA cases were more likely to correctly recognize NA items (Z=-2.428,P=0.015;Z=-2.028,P=0.043;Z=-2.534,P=0.011). Besides, female students got higher scores of CSQ-CV (Z=-2.000, P=0.045). Nursing undergraduates’ recognition of EA, especially in neglect and PA are still at a low level in China. Education about EA in nursing undergraduates’ curriculum and training program should be encouraged.
21
Bäni, Lukas, Andreas Alexopoulos, Marina Artuso, Felix Bachmair, Marcin Bartosik, Helge Beck, Vincenzo Bellini, et al. "A Study of the Radiation Tolerance of CVD Diamond to 70 MeV Protons, Fast Neutrons and 200 MeV Pions." Sensors 20, no. 22 (November 20, 2020): 6648. http://dx.doi.org/10.3390/s20226648.
Анотація:
We measured the radiation tolerance of commercially available diamonds grown by the Chemical Vapor Deposition process by measuring the charge created by a 120 GeV hadron beam in a 50 μm pitch strip detector fabricated on each diamond sample before and after irradiation. We irradiated one group of samples with 70 MeV protons, a second group of samples with fast reactor neutrons (defined as energy greater than 0.1 MeV), and a third group of samples with 200 MeV pions, in steps, to (8.8±0.9) × 1015 protons/cm2, (1.43±0.14) × 1016 neutrons/cm2, and (6.5±1.4) × 1014 pions/cm2, respectively. By observing the charge induced due to the separation of electron–hole pairs created by the passage of the hadron beam through each sample, on an event-by-event basis, as a function of irradiation fluence, we conclude all datasets can be described by a first-order damage equation and independently calculate the damage constant for 70 MeV protons, fast reactor neutrons, and 200 MeV pions. We find the damage constant for diamond irradiated with 70 MeV protons to be 1.62±0.07(stat)±0.16(syst)× 10−18 cm2/(p μm), the damage constant for diamond irradiated with fast reactor neutrons to be 2.65±0.13(stat)±0.18(syst)× 10−18 cm2/(n μm), and the damage constant for diamond irradiated with 200 MeV pions to be 2.0±0.2(stat)±0.5(syst)× 10−18 cm2/(π μm). The damage constants from this measurement were analyzed together with our previously published 24 GeV proton irradiation and 800 MeV proton irradiation damage constant data to derive the first comprehensive set of relative damage constants for Chemical Vapor Deposition diamond. We find 70 MeV protons are 2.60 ± 0.29 times more damaging than 24 GeV protons, fast reactor neutrons are 4.3 ± 0.4 times more damaging than 24 GeV protons, and 200 MeV pions are 3.2 ± 0.8 more damaging than 24 GeV protons. We also observe the measured data can be described by a universal damage curve for all proton, neutron, and pion irradiations we performed of Chemical Vapor Deposition diamond. Finally, we confirm the spatial uniformity of the collected charge increases with fluence for polycrystalline Chemical Vapor Deposition diamond, and this effect can also be described by a universal curve.
22
Lyashchevskaya, M. S., V. B. Bazarova, and T. R. Makarova. "ENVIRONMENT DEVELOPMENT AND THE EVOLUTION OF GNILOE LAKE (SOUTH-EASTERN PRIMORYE) DURING THE LAST 3300 YEARS<a href="#FN1"><sup>1</sup></a>." Геоморфология и палеогеография 54, no. 3 (July 1, 2023): 108–23. http://dx.doi.org/10.31857/s2949178923030064.
Анотація:
A continuous record of paleogeographic events in south-eastern Primorye has been reconstructed based on the deposits of Gniloe Lake. The lake is located on the northern coast of Nakhodka Bay. Starting from 3240 cal. BP. 5 warming periods were identified: 3240–2500, 1865–1653, 1330–838, 733–624 cal. BP and from the second half of the 17th century to the present; 4 periods of cooling: 2500–1865, 1653–1330, 838–733 and 624–322 cal. BP; 6 wet periods: 3240–2500, 1865–1653, 1479–1330, 1056–838, 733–624 cal. BP and last 280 years; 5 dry periods: 2500–1865, 1653–1479, 1330–1056, 838–733 and 624–210 cal. BP. According to palynological analysis, the expansion of Pinus koraiensis and dark coniferous species occurred during the second phase of the Mid-Subatlantic cooling of 1479–1330 cal. BP. In the last 150 years, the most significant changes have been associated with the anthropogenic transformation of landscapes as a result of urbanization. The area of forests and their species composition have decreased. At present, shrubs have occupied areas of the deforested oak forests. Based on the results of diatom analysis, 7 stages of the development of Gniloe Lake were identified. There was a shallow semi-open lagoon at a sea level 1–1.5 m higher than the present day about 3240 cal. BP. Cooling and decrease in humidity about 2500 cal. BP led to the formation of a slightly saline semi-enclosed lagoon. Shallowing of the lagoon about 2000 cal. BP was due to a decrease in sea level. Finally, the lagoon separated from the sea about 1450 cal. BP. The transformation of the lagoon into a fresh lake occurred around 1080 cal. BP. During the period of cooling 840–733 cal. BP the shallowing of the lake began, which continued in the Little Ice Age. The increase of the lake level associated with moderate warming and an increase in humidity began at 210 cal. BP. Traces of three catastrophic events were recorded in the sediments of Gniloe Lake – a high-intensity storm about 3000 cal. BP and 2 tsunamis around 2000 and 1560 cal. BP.
23
Furey, Sandy A., Joel A. Waksman, and Barry H. Dash. "Nonprescription Ibuprofen: Side Effect Profile." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 12, no. 5 (September 10, 1992): 403–7. http://dx.doi.org/10.1002/j.1875-9114.1992.tb04479.x.
Анотація:
Single doses of nonprescription analgesics are commonly used to treat self‐diagnosed conditions. To evaluate the safety of single doses of nonprescriptionstrength ibuprofen, we examined reported side effects from 15 double‐blind, randomized, controlled trials we conducted of the drug to treat various common painful conditions (e.g., headache, sore throat). All studies included placebo and another nonprescription analgesic, acetaminophen. A total of 878 subjects received ibuprofen 200 or 400 mg, 849 acetaminophen 650 or 1000 mg, and 852 placebo. The overall frequency of side effects was comparable: ibuprofen 2.4%, acetaminophen 3.2%, and placebo 2.1%. The frequency of central nervous system symptoms was 0.8%, 2.1%, and 0.9%, respectively. Upper gastrointestinal upset ranged from 0.8–0.9% of subjects in all groups. We conclude that single doses of nonprescription ibuprofen are well tolerated and demonstrate a side effect profile indistinguishable from that of acetaminophen and placebo.
24
Yan, Xieqiao, Siming Li, Zhihong Chi, Lu Si, Chuanliang Cui, Yan Kong, Li Zhou, et al. "Systemic therapy in patients with metastatic Xp11.2 translocation renal cell carcinoma." Journal of Clinical Oncology 40, no. 6_suppl (February 20, 2022): 341. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.341.
Анотація:
341 Background: Xp11.2 translocation renal cell carcinoma (RCC) is a unique RCC subtype with high malignant potential and poor prognosis, its natural course and response to systemic therapy are not fully understood. We analyzed the clinic features of this distinct entity and the benefit of systemic therapy in these patients. Methods: Between May 2006 and December 2019, 1113 consecutive patients diagnosed with RCC from Peking university cancer hospital (Beijing, China) were reviewed, data of the clinical characteristics and outcome of patients with metastatic Xp11.2 RCC were retrospectively collected. Tumor response to systemic therapy was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS) distributions. Results: Metastatic Xp11.2 tRCC was found in 45 patients. The median PFS and median OS was 7.4 months (4.5 - 8.8) and 17.9 months (12.4 - 24.4), respectively. First-line treatment mainly included sunitinib (n = 14), sorafenib (n = 15), axitinib (n = 6), and pazopanib (n = 5), and the median PFS of these regimens were 7.4 months, 5.4 months, 9.4 months, 8.9 months, respectively. Two patients who received Vascular endothelial growth factor receptor - tyrosine kinase inhibitor (VEGFR-TKI) plus immune checkpoint inhibitor (ICI) as first line therapy had a PFS of more than 16.6 months and more than 25.6 months, respectively. Twenty-four patients received subsequent therapies, which included VEGFR-TKI/ICI, axitinib and mTOR inhibitor, the median PFS for these regimens was 8.5, 7.2 and 2.0 months, respectively. Patients with serous cavity effusion or IMDC poor risk groups had significantly shorter median PFS and median OS. Conclusions: Metastatic Xp11.2 tRCC is an aggressive disease. VEGFR-TKI agents appeared to demonstrate some efficacy, VEGFR-TKI/ICI combination might be a useful tool for the treatment of metastatic Xp11.2 tRCC.
25
Adeyemo, E. A., D. W. Riepen, G. A. Collett, B. K. Au, and M. H. Huo. "COMPARISON OF TOTAL HIP ARTHROPLASTY VERSUS HEMIARTHROPLASTY IN PATIENTS WITH FEMORAL NECK FRACTURES." Orthopaedic Proceedings 105-B, SUPP_12 (June 23, 2023): 51. http://dx.doi.org/10.1302/1358-992x.2023.12.051.
Анотація:
The current evidence favors replacement for the treatment of displaced femoral neck fractures in the older patients. Controversies remain whether total hip replacement (THR), or hemiarthroplasty (HA) would result in better outcomes. The purpose of this study is to compare the outcomes, and the complications in patients who underwent THR or HA for displaced femoral neck fractures.There were 345 consecutive patients who had undergone either a THR or HA at a single institution. THR was done in 137, and HA was done in 208 patients, respectively. Standard peri-operative data were collected.The mean values for the data in the THR group are: age 69 years, ASA 2.7, OR time was 99 minutes, estimated blood loss 354 ml, and the length of stay 8 days. The mean values for the data in the HA group are: age 75 years, ASA 3.0, OR time 88 minutes, estimated blood loss 200 ml, and the length of stay 10 days. The overall complications were 8.8% (THR), and 9.1% (HA), respectively. The mortality rates for the patients were: at the 1-year (9.5% THR vs 16.3% HA), at the 3-year (15.3% THR vs 24.0% HA), and at the 5-year (19.7% THR vs 26.9% HA), respectively.Our data demonstrated similar peri-operative data and short-term complications between the two groups. There was a difference in the mortality rates between the two groups at all 3-time intervals following the surgery. This could be a reflection of the patient selection bias for each of the operations.
26
Mann, Pietsch, and Liebert. "Genetic Diversity of Sapoviruses among Inpatients in Germany, 2008−2018." Viruses 11, no. 8 (August 7, 2019): 726. http://dx.doi.org/10.3390/v11080726.
Анотація:
Sapovirus enteric disease affects people of all ages across the globe, in both sporadic cases and outbreak settings. Sapovirus is seldom assessed in Germany and its epidemiology in the country is essentially unknown. Thus, sapovirus occurrence and genetic diversity were studied by real-time reverse transcription polymerase chain reaction (RT-PCR) and partial sequencing of major viral structural protein (VP1) gene in two different sets of stool samples: 1) a selection of 342 diarrheal stools collected from inpatient children during 2008−2009, and 2) 5555 stool samples collected during 2010–2018 from inpatients of all age groups with gastrointestinal complaints. Results showed year-round circulation of sapoviruses, with peaks during cooler months. In total, 30 samples (8.8%) of the first and 112 samples of the second set of samples (2.0%) were sapovirus positive. Capsid gene sequencing was successful in 134/142 samples (94.4%) and showed circulation of all known human pathogenic genogroups. Genotype GI.1 predominated (31.8%), followed by GII.1 (16.7%), GII.3 (14.5%), GI.2 (13.8%) and GV.1 (12.3%). Additionally, minor circulation of GI.3, GI.6, GII.2, GII.4, GII.6 and GIV.1 was shown. Consequently, sapovirus diagnostics need broadly reactive RT-PCR protocols and should particularly be considered in infants and young children. Further studies from other sampling sites are essential to extend our knowledge on sapovirus epidemiology in Germany.
27
Ye, Ting, Haoxuan Wu, Shengping Wang, Qiao Li, Yajia Gu, Junjie Ma, Jihong Lin, et al. "Radiologic Identification of Pathologic Tumor Invasion in Patients With Lung Adenocarcinoma." JAMA Network Open 6, no. 10 (October 16, 2023): e2337889. http://dx.doi.org/10.1001/jamanetworkopen.2023.37889.
Анотація:
ImportanceIt is currently unclear whether high-resolution computed tomography can preoperatively identify pathologic tumor invasion for ground-glass opacity lung adenocarcinoma.ObjectivesTo evaluate the diagnostic value of high-resolution computed tomography for identifying pathologic tumor invasion for ground-glass opacity featured lung tumors.Design, Setting, and ParticipantsThis prospective, multicenter diagnostic study enrolled patients with suspicious malignant ground-glass opacity nodules less than or equal to 30 mm from November 2019 to July 2021. Thoracic high-resolution computed tomography was performed, and pathologic tumor invasion (invasive adenocarcinoma vs adenocarcinoma in situ or minimally invasive adenocarcinoma) was estimated before surgery. Pathologic nonadenocarcinoma, benign diseases, or those without surgery were excluded from analyses; 673 patients were recruited, and 620 patients were included in the analysis. Statistical analysis was performed from October 2021 to January 2022.ExposurePatients were grouped according to pathologic tumor invasion.Main Outcomes and MeasuresPrimary end point was diagnostic yield for pathologic tumor invasion. Secondary end point was diagnostic value of radiologic parameters.ResultsAmong 620 patients (442 [71.3%] female; mean [SD] age, 53.5 [12.0] years) with 622 nodules, 287 (46.1%) pure ground-glass opacity nodules and 335 (53.9%) part-solid nodules were analyzed. The median (range) size of nodules was 12.1 (3.8-30.0) mm; 47 adenocarcinomas in situ, 342 minimally invasive adenocarcinomas, and 233 invasive adenocarcinomas were confirmed. Overall, diagnostic accuracy was 83.0% (516 of 622; 95% CI, 79.8%-85.8%), diagnostic sensitivity was 82.4% (192 of 233; 95% CI, 76.9%-87.1%), and diagnostic specificity was 83.3% (324 of 389; 95% CI, 79.2%-86.9%). For tumors less than or equal to 10 mm, 3.6% (8 of 224) were diagnosed as invasive adenocarcinomas. The diagnostic accuracy was 96.0% (215 of 224; 95% CI, 92.5%-98.1%), diagnostic specificity was 97.2% (210 of 216; 95% CI, 94.1%-99.0%); for tumors greater than 20 mm, 6.9% (6 of 87) were diagnosed as adenocarcinomas in situ or minimally invasive adenocarcinomas. The diagnostic accuracy was 93.1% (81 of 87; 95% CI, 85.6%-97.4%) and diagnostic sensitivity was 97.5% (79 of 81; 95% CI, 91.4%-99.7%). For tumors between 10 to 20 mm, the diagnostic accuracy was 70.7% (220 of 311; 95% CI, 65.3%-75.7%), diagnostic sensitivity was 75.0% (108 of 144; 95% CI, 67.1%-81.8%), and diagnostic specificity was 67.1% (112 of 167; 95% CI, 59.4%-74.1%). Tumor size (odds ratio, 1.28; 95% CI, 1.18-1.39) and solid component size (odds ratio, 1.31; 95% CI, 1.22-1.42) could each independently serve as identifiers of pathologic invasive adenocarcinoma. When the cutoff value of solid component size was 6 mm, the diagnostic sensitivity was 84.6% (95% CI, 78.8%-89.4%) and specificity was 82.9% (95% CI, 75.6%-88.7%).Conclusions and relevanceIn this diagnostic study, radiologic analysis showed good performance in identifying pathologic tumor invasion for ground-glass opacity–featured lung adenocarcinoma, especially for tumors less than or equal to 10 mm and greater than 20 mm; these results suggest that a solid component size of 6 mm could be clinically applied to distinguish pathologic tumor invasion.
28
Přibyl, J., J. Haman, T. Kott, J. Přibylová, M. Šimečková, L. Vostrý, L. Zavadilová, et al. " Single-step prediction of genomic breeding value in a small dairy cattle population with strong import of foreign genes." Czech Journal of Animal Science 57, No. 4 (April 27, 2012): 151–59. http://dx.doi.org/10.17221/5890-cjas.
Анотація:
The breeding value (EBV) of Holstein cattle milk performance from the first lactation was evaluated using a regular Animal Model or by Single-Step Prediction of the genomic breeding value (GEBV). A total of 838 bulls were genotyped using the Illumina BovineSNP50 Beadchip V2. Two overlapping sets of milk performances were evaluated: calving years 1991–2004, with 729 341 lactations and 1 394 487 animals in the pedigree and calving years 1996–2009, with 808 436 lactations and 1 487 608 animals in the pedigree. The older data set included 526 genotyped bulls, in which the daughters’ milk performance was known for 210 individuals. All of the genotyped animals were included in the newer data set. Of the young genotyped bulls from the older set, 279 had more than 50 daughters with performance records in the newer set. Genomic relationship matrices (G) were constructed from the allele frequencies of the current genotyped population or by assuming a constant value of 0.5 for all loci. Using current allele frequencies, the correlation of G with the pedigree relationship (A) was 0.74, while it was 0.77 when the constant value was used. G was blended with A with weights of 80 or 99%. The average EBV of the genotyped bulls exceeded the mean EBV of the entire population by 3 SD. Although the number of reference bulls was small, genotyping resulted in an increase of approximately 0.05 in the correlation of the GEBV of young bulls with their results after progeny testing. Only small differences in correlations were found in dependency on the methods used for the determination of G and in dependency on the weight used in blending G with A. Both EBV and GEBV in the older set showed higher correlations with the GEBV of the newer set than the EBV of the newer set.
29
ATWILL, EDWARD R., KENNETH W. TATE, MARIA das GRACAS CABRAL PEREIRA, JAMES BARTOLOME, and GLENN NADER. "Efficacy of Natural Grassland Buffers for Removal of Cryptosporidium parvum in Rangeland Runoff." Journal of Food Protection 69, no. 1 (January 1, 2006): 177–84. http://dx.doi.org/10.4315/0362-028x-69.1.177.
Анотація:
Our goal for this project was to estimate the retention efficiency of natural grassland buffers for Cryptosporidium parvum. Three sets of 16 plots (2.0 by 3.0 m) were established at 5, 20, and 35% slopes. Within each set of 16 plots, residual dry vegetation matter treatments of 225, 560, and 900 kg/ha were implemented, along with a noncut control averaging 4,500 kg/ha. Buffer width treatments were implemented by placing cattle fecal material containing known loads of C. parvum 0.1, 1.1, or 2.1 m up-slope of the runoff collector. Grassland buffers of 1.1 and 2.1 m generated 3.2- to 8.8-log and 3.6- to 8.8-log retention of C. parvum, respectively, across the range of residual dry vegetation matter, land slope, rainfall, and runoff conditions examined during this project. Buffers with an increased percent land slope exhibited improved the retention efficiencies, whereas buffers experiencing larger maximum annual runoff events exhibited reduced retention efficiencies. Water-quality data from the 0.1-m-wide buffer plots (effectively no buffer) demonstrated that the majority of C. parvum oocysts (98 to 99.999%) were retained in the fecal matrix for the duration of the storm season, irrespective of the presence of a vegetated buffer. In conclusion, these results support the assertion that grassland buffers are an effective method for reducing animal agricultural inputs of waterborne C. parvum into drinking and irrigation water supplies.
30
Huang, Vivian Wai-Mei, Neil Dhami, Darryl Fedorak, Connie Prosser, Carol Shalapay, Karen Ivy Kroeker, Brendan Phillip Halloran, Levinus Albert Dieleman, and Richard Neil Fedorak. "A Study Investigating the Association of Dermatological and Infusion Reactions to Infliximab and Infliximab Trough Levels." Canadian Journal of Gastroenterology and Hepatology 29, no. 1 (2015): 35–40. http://dx.doi.org/10.1155/2015/428702.
Анотація:
BACKGROUND: Although infliximab is an effective therapy for inflammatory bowel disease (IBD), it is associated with dermatological events and infusion reactions. It is not known whether a relationship between these adverse events (AEs) and infliximab trough levels (ITLs) exists.OBJECTIVES: To report the prevalence of infliximab-associated AEs in IBD patients receiving stable maintenance infliximab therapy, and to correlate ITLs with dermatological and infusion reactions to infliximab.METHODS: Adult IBD patients receiving stable maintenance infliximab therapy were recruited from the University of Alberta Infusion Clinic (Edmonton, Alberta). ITLs were measured in blood samples collected before infusion, and the patients’ records were reviewed for dermatological and infusion reactions to infliximab.RESULTS: One-quarter (18 of 71 [25.4%]) of patients experienced dermatological or infusion reactions to infliximab: nine (12.7%) dermatological events and nine (12.7%) infusion reactions. The median ITL was similar among patients with and without these AEs (7.2 μg/mL [interquartile range (IQR) 2.0 μg/mL to 13.3 μg/mL] versus 6.6 μg/mL [IQR 3.2 μg/mL to 12.7 μg/mL]; P=0.648). The median ITL of patients who experienced infusion reactions (2.0 μg/mL [IQR 0.1 μg/mL to 5.7 μg/mL]) was lower than that of patients who experienced no such AEs (6.6 μg/mL [IQR 3.2 μg/mL to 12.7 μg/mL]; P=0.008]) and lower than that of patients who experienced dermatological AEs (13.3 μg/mL [IQR 8.8 μg/mL to 17.4 μg/mL]; P<0.001).CONCLUSION: One-quarter of IBD outpatients receiving stable maintenance infliximab therapy experienced dermatological and infusion reactions. Low ITLs were correlated with infusion reactions, and normal or high ITLs with dermatological events.
31
Alsterholm, Mikael, Axel Svedbom, Chris D. Anderson, Lena Holm Sommar, Lina U. Ivert, Anna Josefson, Laura Von Kobyletzki, et al. "Establishment and Utility of SwedAD: A Nationwide Swedish Registry for Patients with Atopic Dermatitis Receiving Systemic Pharmacotherapy." Acta Dermato-Venereologica 103 (April 6, 2023): adv7312. http://dx.doi.org/10.2340/actadv.v103.7312.
Анотація:
SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmacotherapy, was launched on 1 September 2019. We describe here the establishment of a user-friendly registry to the benefit of patients with atopic dermatitis. By 5 November 2022, 38 clinics had recorded 931 treatment episodes in 850 patients with an approximate national coverage rate of 40%. Characteristics at enrolment included median Eczema Area and Severity Index (EASI) 10.2 (interquartile range 4.0, 19.4), Patient-Oriented Eczema Measure (POEM) 18.0 (10.0, 24.0), Dermatology Life Quality Index (DLQI) 11.0 (5.0, 19.0) and Peak Itch Numerical Rating Scale-11 (NRS-11) 6.0 (3.0, 8.0). At 3 months, median EASI was 3.2 (1.0, 7.3) and POEM, DLQI, and NRS-11 were improved. Regional coverage varied, reflecting the distribution of dermatologists, the ratio of public to private healthcare, and difficulties in recruiting certain clinics. This study highlights the importance of a nationwide registry when managing systemic pharmacotherapy of atopic dermatitis.
32
Tumanan-Mendoza, Bernadette A., Victor L. Mendoza, April Ann A. Bermudez-Delos Santos, Felix Eduardo R. Punzalan, Noemi S. Pestano, Rudy Boy Natividad, Louie Alfred Shiu, Renelene Macabeo, and Hilton Y. Lam. "Economic burden of hospitalisation for congestive heart failure among adults in the Philippines." Heart Asia 10, no. 2 (October 2018): e011039. http://dx.doi.org/10.1136/heartasia-2018-011039.
Анотація:
ObjectivesHospitalisation for congestive heart failure (CHF) was reported to be 1648 cases for every 100 000 patient claims in 2014 in the Philippines; however, there are no data regarding its economic impact. This study determined CHF hospitalisation cost and its total economic burden. It compared the healthcare-related hospitalisation cost from the societal perspective with the payer’s perspective, the Philippine Health Insurance Corporation (PhilHealth).MethodsThis is a cost analysis study. Data were obtained from representative government/private hospitals and a drugstore in all regions of the country. Healthcare costs included cost of diagnostics/treatment, professional fees and other CHF-related hospital charges, while non-healthcare costs included production losses, transportation and food expenses.ResultsThe overall mean healthcare-related cost for CHF hospitalisation (class III) in government hospitals in the Philippines in 2014 was PHP19 340–PHP28 220 (US$436–US$636). In private hospitals, it was PHP28 370–PHP41 800 (US$639–US$941). In comparison, PhilHealth’s coverage/CHF case rate payment is PHP15 700 (US$354). The mean non-healthcare cost was PHP10 700–PHP14 600 (US$241–US$329). Using PhilHealth’s case rate payment and the prevalence of CHF hospitalisation in 2014, the total economic burden was PHP691 522 200 (US$15 574 824). Using the study results on healthcare-related cost meant that the total economic burden for CHF hospitalisation would instead be PHP851 850 000–PHP1 841 563 000 (US$19 185 811–US$41 476 644).ConclusionsThe calculated healthcare-related hospitalisation cost for CHF in the Philippines in 2014 demonstrates the disparity between the actual cost and PhilHealth’s coverage. This implies a need for policymakers to review its coverage to make healthcare delivery affordable.
33
Kutluk, M. Tezer, and Akif Yeşilipek. "Pediatric cancer registry in Turkey 2009-2019 (TPOG & TPHD)." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e22513-e22513. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e22513.
Анотація:
e22513 Background: The pediatric cancer registry is an essential element of pediatric cancer control. More than 200000 pediatric cancer cases annually are expected in children and adolescents aged 0-14 globally. The current efforts are focusing to improve the survival rates for children and adolescents in LMICs since the survival has already exceeded 80% in most of the high income countries. Here we present the most updated results of the pediatric cancer registry in Turkey. Methods: Pediatric cancer registry has been established by theTurkish Pediatric Oncology Group and Turkish Pediatric Hematology Association in 2002. The childhood cancer cases registered between 2009-2019 was included in this analysis. International Childhood Cancer Classification System was used for the classification. Essential demographic findings, ICD-O-3 morphology and topography codes were recorded for each case. Results: During the 11 years from 2009 to 2019, 17770 cases were registered. For all cases, median age was 6.8 year (0-17; M/F 9973/7789, 3 hermaphrodite, 5 unknown). Age distribution was 0-4 yrs, 40.3%; 5-9 yrs, 24.0%; 10-14 yrs, 23.6%; 15-19 yrs, 12.1%) The distribution of the tumor types were [number of cases, percentage of total, median age yrs, M/F]: Leukemia (4570, 25.7%, 5.5, 2633/1937); Lymphoma & other RES tumors (3477, 19.6%, 9.9, 2324/1150, 1 hermaphrodite & 2 unknown); CNS [brain & spinal] (2493, 14.0%, 6.9, 1363/1129, 1 unkown); Symphatetic system (1426, 8.0%, 2.4, 743/683); Retinoblastoma (348, 2.0%, 1.5, 204/144); Renal (905, 5.1%, 3.2, 435/469, 1 unknown); Liver (304, 1.7%, 1.8, 172/132); Malignant bone (1209, 6.8%, 12.6, 658/551); Soft tissue sarcomas (1221, 6.9%, 7.5, 703/518); Germ cell (1165, 6.6%, 8.8, 426/736, 2 hermaphrodite, 1 unknown); Carcinoma & other malignant epithelial (533, 3.0%, 13.8, 254/279); Other/non-specific malignant (119, 0.7%, 8.5, 58/61). Five year survival rate was found as 71.9%. Conclusions: The data is the most essential part of the cancer control.This registry has been used widely among professionals since its establishment in 2002. Survival rates for children and adolescents has been improved to 70%. This is at the acceptable level for the income level of Turkey which is classified as an upper middle income country. The registry is a useful source for investigators and decision makers at national and international level.
34
Баязитова, Кульбарам, Аяз Рамазанов, Елена Иль, Дмитрий Иль, Тлеуберген Баязитов та Гульзат Кощугулова. "ОПРЕДЕЛЕНИЕ ДОЗЫ СЕЛЕНОСОДЕРЖАЩИХ ПРЕПАРАТОВ В РАЦИОНЕ СТЕЛЬНЫХ СУХОСТОЙНЫХ КОРОВ". Ġylym ža̋ne bìlìm 2, № 3(72) (25 вересня 2023): 233–41. http://dx.doi.org/10.52578/2305-9397-2023-3-2-233-241.
Анотація:
В статье рассматриваются вопросы выяснения оптимальной дозы селена в рационе стельных сухостойных коров на одной из молочно-товарных ферм Северо-Казахстанской области. Для этого были сформированы 4 группы коров (контрольная, Ⅰ опытная – с дозой 1,25 мг, Ⅱ опытная – 3,9 мг, ⅡⅠ опытная – 6,7 мг на 1 голову в сутки). Включение в рацион стельных сухостойных коров 3,9 мг селенита натрия повлияла на прирост живой массы, воспроизводительную функцию и качество приплода. За период сухостоя изменение живой массы контрольной группы коров заметно отставало от опытных групп, разница составила 6,6 кг, 8,8 кг и 6,8 кг соответственно при достоверности Р>0,999.
Введение в рацион селенита натрия благотворно отразилось на продолжительности сервис-периода. Так сокращение сервис-период до 71 дня при дозе селена 3,9 мг, позволило на 21 день опередить наступление плодотворного осеменения коров по сравнению с контрольной группой.
Добавление в рацион кормления селенита натрия в дозе 3,9 мг на голову оказало заметное влияние на качество и количество молозива, о чем свидетельствует более интенсивный прирост живой массы новорожденных телят по сравнению с остальными группами (более 4 кг, в контроле 3,2 кг) при Р>0,95.
35
Sawattep, Jeeranut, Thad A. Howard, Noppawan P. Morales, Yupin Sanvarinda, Pranee Fucharoen, Suthat Fucharoen, and Russell E. Ware. "Single Nucleotide Polymorphism (SNP) Discovery within the UGT1A Gene Complex: Allelic Frequencies and Ethnic Differences." Blood 104, no. 11 (November 16, 2004): 3780. http://dx.doi.org/10.1182/blood.v104.11.3780.3780.
Анотація:
Abstract The UDP-glycosyltransferase (UGT1A) gene complex plays an important role in the hepatic metabolism of many chemicals, toxins, and drugs including bilirubin and acetaminophen. In this large gene complex that spans over 200kb, there are at least 13 different coding regions that can serve as exon 1, followed by a common sequence that contains exons 2–5. These variable exon 1 sequences confer different chemical specificities for binding compounds, while exons 2–5 provide glycosyltransferase function (glucuronidation) that enhances water solubility and excretion. Mutations and polymorphisms within the UGT1A complex may help explain the phenotypic variability that is observed in drug metabolism for patients with hematological diseases. To date, several important polymorphisms have been identified in the coding regions of the UGT1A1 and UGT1A6 exon 1 sequences, but formal single nucleotide polymorphism (SNP) discovery has not been reported. Using genomic DNA obtained from a cohort of Thai patients with beta-thalassemia/HbE (n=37) and African-American patients with sickle cell anemia (n=12), flanking and coding sequences for UGT1A1 exon 1 (1.5kb), UGT1A6 exon 1 (1.5kb), and UGT1A common exons 2–5 (2.5kb) were fully sequenced in both directions. Polymorphisms that occurred more than once were compared to wildtype sequences obtained from NCBI, Accession Number AF297093. Single Nucleotide Polymorphisms in the UGT1A gene complex SNP NCBI nucleotide Location African-American Thai * indicates a SNP previously identified in NCBI g/c 109183 5′ 1A6 Exon 1 .875/.125 .676/.324 c/g 109301 5′ 1A6 Exon 1 .833/.167 1.000/.000 g/t 109628 1A6 Exon 1 .458/.542 .662/.338 c/t 109713 1A6 Exon 1 1.000/.000 .905/.095 a/g * 109924 1A6 Exon 1 .542/.458 .689/.311 a/g * 110150 1A6 Exon 1 .708/.292 .689/.311 a/c * 110161 1A6 Exon 1 .625/.375 .662/.338 t/g 110236 1A6 Exon 1 .750/.250 .973/.027 c/t 174679 5′ 1A1 Exon 1 .500/.500 .770/.230 g/c 174979 5′ 1A1 Exon 1 1.000/.000 .946/.054 g/a * 175253 1A1 Exon 1 1.000/.000 .932/.068 a/g 182226 Intron 2 .955/.045 .689/.311 t/c 182521 Intron 2 .850/.150 .905/.095 c/t 187524 3′ Exon 5 .417/.583 .865/.135 c/g * 187652 3′ Exon 5 .625/.375 .851/.149 c/g * 187753 3′ Exon 5 .587/.417 .838/.162 In addition to the well-described UGT1A1 (TA)n promoter polymorphism, a total of 16 SNPs were identified in these regions, including 10 that have not been previously reported. Four novel promoter SNPs were identified, along with three new UGT1A6 exon 1 coding SNPs and three non-coding SNPs within the common exon 2–5 region. The alellic frequencies for these SNPs can only be estimated from this small sample size, but indicate substantial differences between Thai and African-American patients. A larger sample size will be used to determine a more accurate allelic frequency for each SNP, and to identify haplotype associations. These novel SNPs within the UGT1A gene complex may have important effects on drug metabolism and may explain some of the phenotypic variability observed in these patient populations.
36
Tkalenko, G., and S. Goral. "Features of the formation of a phytopathogenic complex on tomatoes in greenhouses." Interdepartmental Thematic Scientific Collection of Plant Protection and Quarantine, no. 65 (December 20, 2019): 191–200. http://dx.doi.org/10.36495/1606-9773.2019.65.191-200.
Анотація:
Goal. Conduct phytopathological monitoring of tomato plantings in greenhouses, study the dynamics of the spread and development of diseases.
Methods. The studies were carried out according to the methods generally accepted in phytopathology, the results of the studies were processed statistically. Results. It was found that for 2002—2019. Research throughout the growing season (from the emergence of seedlings to the end of the growing season), tomatoes in greenhouses when grown on different substrates (soils and mineral wool) are largely affected by fungal and bacterial diseases, to a lesser extent by viral diseases. Among the diseases of tomatoes, root and gray rot, fusarium wilting, brown spot prevail, which affect crops within 21.8—86.3% in ground greenhouses and 18.4—61.7% on mineral wool. The intensity of manifestation of bacterial diseases increased, the prevalence of which was 48—63.3% on soils and 51.5—78.5% on mineral wool, with the development of 19.0—27.5% and 25.8—28.3%, respectively. Viral diseases are less common — 7.5—10.5% with the development of 3.9—4.3% for soil mixture and 8.8—13.4% with the development of 4.4—5.8% for mineral wool. Among the nonparasitic diseases, tomato apical rot is dominant. When grown on soils, the infestation of fruits was 18.7%, maximum — 27.5%, and development — 4.3—7.0%. With a low-volume growing technology, the spread reached 16.6—31.1%, while the development was 3.2—4.1%.
Conclusions. On planting tomatoes in greenhouses, regardless of the greenhouse substrates, there is a stable complex of fungal, bacterial, viral and nonparasitic diseases, and their harmfulness depends on the cultivation technology. Tomatoes during the growing season are affected not by one type of pathogen, but by their complex. The phytopathological complex of tomatoes in greenhouses is dynamic, which requires constant study and protective measures.
37
Bernaudin, Francoise, Emmanuelle Lesprit, Lena Coïc, Cécile Arnaud, Emmanuelle Fleurence, Suzanne Verlhac, and Christophe Delacourt. "Long Term Prospective Follow-Up after Treatment Intensification in Pediatric Sickle Cell Patients: Comparative Effects of Transfusion Program (TP), Hydroxyurea (HU) or Stem Cell Transplant (SCT) on Annual Check-Ups." Blood 106, no. 11 (November 16, 2005): 3196. http://dx.doi.org/10.1182/blood.v106.11.3196.3196.
Анотація:
Abstract Treatment intensifications in SCD with HU, TP or SCT are applied in order to reduce SCD related complications but their comparative effects have still to be described. We report our experience concerning the annual check-up performed in SCD pediatric patients. Patients and Methods: Among our cohort of 397 SS/Sb0 pediatric SCD patients, 157 of them were intensified with HU (n= 86), TP (n=104) or SCT (n=36) and some of them received successively HU, TP and SCT. HU was proposed to patients > 3 years of age and having experienced more than 3 VOC/ACS/year or < 7g/dl severe anemia. TP defined as > 4 months program was applied in patients with cerebral vasculopathy defined by an history of stroke or abnormal TCD (> 200 cm/sec). TP was also proposed in patients with HU-failure and in patients with frequent VOC, less than 3 years old. SCT was proposed in patients with an indication of treatment intensification and an available HLA identical sibling donor. Annual check-up were performed in our day-care unit. We analysed 1261 check-ups performed and recorded since 1992 in 341 SS/Sb0 patients (sex: 164 F, 177 M). Median age was 8.8 ± 5.1 years. Mean number of annual check-ups per patient was 3.7 ± 2.8 (range 1 to 13): 816 were performed in non intensified patients, 196 in HU, 123 in TP and 126 in transplanted patients. Categories of age were distinguished: < 2 y of age (n=110), 2–5y (n=244), 5–10y (n=415), 10–15y (n=317) and 15–20y (n=175). Results: Respective follow-up were 4.4 y ± 3.3 in HU, 2.6 y ± 2.6 inTP and 5.8 y ± 4.7 in SCT patients. Comparison with non intensified patients showed that weight was significantly higher in SCT patients > 15 y of age (p=0.001), spleen size was significantly higher in (2–5y) young patients treated with HU (p=0.005) or TP (0.001) and in 5–10 y old patients on HU (p=0.046) but no difference was observed after the age of 10 y. O2 saturation was significantly improved after SCT (p<0.001) (98.8 ± 1.0 vs 97.1 ± 2.6) and was unchanged on HU and TP. Cardiac pulsations were significantly (p<0.001) decreased after all type of intensification. Biological data are shown (table1and 2). Conclusion : Treatment intensifications (TP, HU, SC) reduced the decrease of weight observed with aging in SCD patients and significantly reduced anemia using different mechanisms. SCT was the most effective to correct anemia, supress hemolysis and decrease leucocytosis. Intensif. n Follow-up HbF% Eryht Hb MCV Retic mean (SD) No 816 11.4 (9.2) 3.1 (0.9) 8.1 (1.2) 81.4 (8.9) 268.9 (105.2) HU 196 4.4 y. (3.3) 13.9 (7.0) 2.7 (0.6) 8.5 (1.2) 97.7 (13.7) 188 (83.8) TP 126 2.6 y.(2.7) 3.3 (3.1) 3.1 (0.6) 9.1 (1.4) 86.8 (4.8) 258.2 (126.0) SCT 123 5.8 y.(4.7) 4.6 (6.4) 4.3 (0.9) 11.4 (1.6) 81.5 (8.9) 89.4 (63.4) Intensif. n Tot Bili Conj Bili LDH Ferritin Leucocytes Platelets No 816 49.8 (34.4) 5.7 (3.4) 1016 (312) 192 (322) 13.2 (9.9) 385 (124) HU 196 47.5 (34.4) 5.0 (2.2) 943 (264) 399 (582) 9.7 (3.8) 352 (133) TP 126 58.8 (39.6) 5.6 (2.2) 973 (377) 2238 (6310) 13.1 (4.7) 365 (128) SCT 123 15.6 (13.9) 2.8 (4.2) 493 (200) 1099 (1386) 6.8 (3.3) 295 (109)
38
Benakli, Malek, Arezki Tibiche, Nabil Yafour, Kamila Amani, Farah Bouamama, Leila Charef, Samira Bouchama, et al. "Autologous Stem Cell Transplantation for Multiple Myeloma in Algeria." Blood 142, Supplement 1 (November 28, 2023): 4973. http://dx.doi.org/10.1182/blood-2023-174045.
Анотація:
Introduction : High dose therapy (HDT) with autologous stem cell transplantation (ASCT) is a validated standard of treatment in eligible patients (pts) with multiple myeloma (MM). It is associated with improved overall and event-free survival compared to conventional chemotherapy. We report here this first large retrospective multicentre study of activity and the outcomes of ASCT in MM pts for a long period (1998-2021) in Algeria. Patients and methods: Over a period of 23 years, from April 1998 to December 2021, 1117 pts with MM (mainly of the IgG type: 604 pts, 54.1%) benefited from ASCT in 8 Algerian centers (Oran: 478, Algiers CPMC: 376, Batna: 76, Blida: 55, Tlemcen: 38, Algiers Military hospital: 32, Oran military hospital: 32, Beni Messous: 30). The median age is 54 years (27 to 78). These are 655 men and 462 women (sex ratio: 1.4). The majority of the pts are at stage III of Salmon and Durie (1024 pts, 91.7%). Several induction protocols were used depending on the period and the department: VAD (200 pts, 17.9%) and Bortezomib-based (799 pts, 80.7%). The diagnosis-transplant delay is on average 12 months (4-137) after the use of one (851 pts; 76.2%) or 2 or more (265 pts; 23.8%) of therapeutic lines. Status disease before intensification: 433 pts (38.8%) were in CR, 312 pts (27.9%) in VGPR and 332 (29.7%) in partial remission. Conditioning based on Melphalan 140 or 200 mg/m2 is widely used (977 pts, 87.4%), followed by reinjection of grafts made of PBSC obtained after mobilization by G-CSF alone, administered, at a dose of 10 at 15 µg/kg/d, including 755 (67.6%) no-cryopreserved cells. Results: The median time to aplasia is 9 days (3-39). G-CSF was used systematically in 364 pts (32.6%). The evaluation carried out in the 3 months following the intensification: 740 pts (66.2%) are in CR, 202 pts (18.1%) in VGPR and 75 pts (6.7%) in PR. Fifteen pts (1.3%) died of early procedure-related complications. Six hundred and twenty-one pts (55.6%) received consolidation treatment combining Bortezomid (VRD, VCD or VTD) and 614 pts (55%) received maintenance treatment mainly with thalidomide (533 pts, 47.7%). A second autograft was performed in tandem or for relapse in 26 pts (2.3%). The final evaluation is carried out in March 2022. Out of a total of 1095 evaluable pts (98%), 731 pts (65.5%) are alive in RC (528 pts; 48.2%), in VGPR (76 pts; 6.9%) and in PR (36 pts; 3.2%) and 364 pts (32.6%) died mainly from relapse or progression (268 pts, 24%). For all patients, after a median follow-up of 125 months, overall survival is 68.5% at 5 years, 52.1% at 10 years and 25.3% at 23 years. OS and EFS have improved substantially over the last 10 years (2011-2021) compared for the first decade (1999-2010) (p<0,0001). Conclusion: This long-term follow-up study shows the transition from induction treatment made essentially of conventional treatments during the 1st decade to triple combinations of new molecules widely used in the induction treatment of patients eligible for intensification. The possibility of carrying out this procedure without cryopreservation of the cells has made it possible to increase the number of beneficiary pts.
39
Stoenoiu, Maria S., Yanling Zhao, Zhen Yu Zhang, Marilucy Lopez-sublet, Narcis George Manolache, Jennie Zhang, Agnès Pasquet, et al. "INCREASED BLOOD PRESSURE VARIABILITY AND DECREASED HEART RATE VARIABILITY IN OLDER VS. YOUNGER INDIVIDUALS: MARKERS OF DISTURBED CARDIOVASCULAR AUTONOMIC MODULATION WITH AGEING?" Journal of Hypertension 42, Suppl 1 (May 2024): e6. http://dx.doi.org/10.1097/01.hjh.0001019380.44324.d4.
Анотація:
Objective: Cardiovascular regulation is affected by ageing through different mechanisms, including arterial baroreflex dysfunction and increased arterial stiffness, with an impact on blood pressure (BP) and heart rate (HR) variability (V), established risk factors for cardiovascular morbidity and mortality. The aim of this study was to compare BPV and HRV in older vs. younger individuals. Design and method: 1080 hypertensive patients (704 younger, 40-55yrs, YH and 376 older, >=75yrs, OH) underwent 24h BP monitoring (ABPM) from 2018 to 2023. Patients with known dysautonomy, Parkinson or other neurodegenerative diseases were excluded. Short-term BPV indexes including standard deviation (SD), weighted standard deviation (wSD), average real variability (ARV), coefficient of variation (CV), and variability independent of mean (VIM) were estimated over 24h. HRV was assessed by SD and CV of heart rate measured during ABPM. The same analysis was replicated in a sample of 343 untreated individuals from the general population (309 YH; 34 OH). Results: As compared to YH, (mean age: 49.5±4.5yrs), OH (mean age: 80.2±4.5yrs) had significantly higher 24h systolic BPV (SD: 15.7±4.6 vs.13.6±4.0; wSD: 15.5±4.6 vs.13.5±4.0; ARV: 12.3±2.9 vs.10.0±2.7; VIM: 15.8±4.5 vs.13.9±4.0 mm Hg; CV: 12.2±3.5 vs.10.8±3.1%; p<0.001). In contrast, 24h HRV was significantly lower in OH than in YH group (SD: 7.2±3.0 vs. 9.1±3.4 beats/min; CV: 11.5±4.5 vs. 12.8.1±4.5%; p<0.001). Higher tertiles of BPV were associated with higher mean pulse pressure and higher pulsatility (pulse pressure normalized for mean arterial pressure), in both YH and OH. Similar results were obtained when comparing OH vs. YH individuals in the general population sample, both for 24h systolic BPV (SD: 14.7±3.1 vs.12.2±2.8; wSD: 14.9±3.1 vs.12.7 ±3.0; ARV: 11.5±2.1 vs.9.2±2.0; VIM: 13.6±2.5 vs.12.3±2.4 mmHg; CV: 11.4±2.1 vs.10.1±2.0%; p<0.01) and HRV (SD: 8.8±3.2 vs. 11.3±3.4 beats/min; CV: 12.7±4.5 vs. 15.1±4.3%; p<0.01). Conclusions: Increased BPV was associated with decreased HRV in older compared to younger individuals, both in a hypertensive cohort and in a general population sample. The respective contribution to these changes of age-related dysfunction of autonomic cardiovascular modulation and increased arterial stiffness and their prognostic implications deserve further investigation.
40
Arevalo, Meily, Myo H. Zaw, Anita Sultan, Sriman Swarup, Nay N. Yee, Wai L. Thein, Myet M. Zin, Nusrat Jahan, and Kyaw Z. Thein. "CLO19-025: Treatment Discontinuation Due to Adverse Events and the Risk of Gastrointestinal Toxicities in Patients With Hematologic Malignancies Treated With Ibrutinib." Journal of the National Comprehensive Cancer Network 17, no. 3.5 (March 8, 2019): CLO19–025. http://dx.doi.org/10.6004/jnccn.2018.7171.
Анотація:
Background: Ibrutinib targets Bruton’s tyrosine kinase, a kinase involved in signaling of B-cell and chemokine receptors, which are implicated in the pathogenesis of hematologic malignancies. Ibrutinib has been shown to improve survival in hematologic malignancies, and yet the tolerability has not been elucidated. We undertook systematic review and pooled analysis of randomized controlled trials (RTCs) to determine the risk of gastrointestinal toxicities and the rate of treatment discontinuation due to adverse events. Methods: We performed a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts through September 2018. Phase 3 RCTs that mention gastrointestinal toxicities and the rate of treatment discontinuation due to adverse events were incorporated in the analysis. Mantel-Haenszel method was used to calculate the estimated pooled risk ratio with 95% CI. Random effects model was applied. Results: 6 phase III RCTs with a total of 1,811 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia were included. Studies comparing ibrutinib vs ofatumumab, ibrutinib vs chlorambucil, ibrutinib + bendamustine + rituximab vs placebo + bendamustine + rituximab, ibrutinib vs temsirolimus, and ibrutinib vs rituximab were included in the analysis. The incidence of treatment discontinuation due to adverse events was 9.30% in the ibrutinib group vs 13.13% in the control arm. The relative risk (RR) for treatment discontinuation was 0.740 (95% CI: 0.385–1.423; P=.367). The pooled RR of all-grade side effects were as follows: diarrhea, 1.955 (95% CI: 1.304–2.933; P=.001); nausea, 1.038 (95% CI: 0.702–1.534; P=.852); vomiting, 1.048 (95% CI: 0.547–2.007; P=.888); and stomatitis, 1.262 (95% CI: 0.112–14.173; P=.850). The RR of high-grade adverse effects were as follows: diarrhea, 1.749 (95% CI: 0.866–3.530; P=.119); nausea, 2.237 (95% CI: 0.478–10.471; P=.306); vomiting, 0.429 (95% CI: 0.111–1.659; P=.220); and stomatitis, 0.309 (95% CI: 0.028–3.440; P=.340). Conclusion: Our study demonstrated that patients on ibrutinib arm noted increased risk of all-grade diarrhea. Nevertheless, other GI toxicities as well as treatment discontinuation due to adverse events were not statistically significant in the ibrutinib group compared with the control arm.
41
Family, Leila, Su-Jau Yang, Zandra Klippel, Yanli Li, John H. Page, Roberto Rodriguez, and Chun Chao. "Risk of Febrile Neutropenia (FN) in Select Myelosuppressive Chemotherapy Regimens." Blood 126, no. 23 (December 3, 2015): 3257. http://dx.doi.org/10.1182/blood.v126.23.3257.3257.
Анотація:
Abstract Introduction Febrile neutropenia (FN) is a serious adverse effect of myelosuppressive chemotherapy, which often results in hospitalization and chemotherapy dose modification. FN risk depends on patient characteristics and chemotherapy regimen risk. Understanding the FN risk associated with individual chemotherapy regimens can help guide the use of prophylactic granulocyte colony-stimulating factor (G-CSF) and patient monitoring. To this end, the NCCN has classified regimens into high (≥20%), intermediate (10%-20%), or low (<10%) FN risk based primarily on clinical trial data. However, even for the same regimen, the FN risk is often higher in clinical practice than in clinical trials. In this study, we assessed the FN risk associated with several regimens for which FN risk has not been determined or has shown substantial variability outside of a clinical trial setting, using data from Kaiser Permanente Southern California (KPSC), a large, community-based practice. Methods Included were patients diagnosed with incident non-Hodgkin's lymphoma (NHL), breast cancer (BC), or multiple myeloma (MM) between 2008 and 2013 at KPSC who initiated the following chemotherapy regimens: bendamustine ± rituximab for NHL; docetaxel, carboplatin, and trastuzumab (TCH) or docetaxel and cyclophosphamide (TC) for BC; or Q4W lenalidomide 25 mg/dexamethasone for MM. Bendamustine ± rituximab, TCH, and lenalidomide are not classified by NCCN; TC is classified as intermediate FN risk but has shown considerable variability of FN incidence when used in clinical practice. Data on cancer diagnosis, chemotherapy use, G-CSF use, neutrophil count, and infections were obtained from KPSC's electronic medical records to estimate the incidence proportions of FN and grade 3 and 4 neutropenia. FN was defined as (1) hospitalization with absolute neutrophil count (ANC) <1000/µL or (2) hospitalization with primary or secondary diagnosis codes of neutropenia (ICD-9 288.0x) and fever (ICD-9 780.6), diagnosis code for bacterial/fungal infection, or antibiotic use. Grade 3 neutropenia was defined as ANC ≥500/µL to <1000/µL; grade 4 neutropenia as ANC <500/µL. Patients who received prophylactic G-CSF within 5 days of chemotherapy initiation were excluded from analysis. Results Overall, 40 (12%) NHL patients; 149 (24%) and 340 (28%) BC patients who received TCH and TC, respectively; and 0 (0%) MM patients were excluded due to prophylactic G-CSF. Over the first 6 cycles of bendamustine (median 338.4 mg/m2) ± rituximab for NHL patients (n = 307), 7.2% experienced FN, 4.2% grade 3 neutropenia, and 17.6% grade 4 neutropenia. Over the first 6 cycles of TCH for BC patients (n = 462), 24.2% experienced FN, 10.6% grade 3 neutropenia, and 44.6% grade 4 neutropenia. Over the first 6 cycles of TC for BC patients (n = 859), 20.5% experienced FN, 9.5% grade 3 neutropenia, and 37.5% grade 4 neutropenia. Over the first 4 cycles of lenalidomide/dexamethasone for MM patients (n = 186), 3.8% experienced FN, 5.9% grade 3 neutropenia, and 18.3% grade 4 neutropenia (Table 1). Conclusions Using NCCN criteria, bendamustine ± rituximab for NHL and lenalidomide/dexamethasone for MM would be classified as low-FN-risk regimens (<10%). By contrast, BC regimens TCH and TC would be classified as high-FN-risk regimens (>20%) based on our data. These results could help inform prophylactic G-CSF use for the selected regimens in clinical practice. Table 1. Number and Incidence Proportion of Neutropenic Outcomes Overall and by Cycle Cancer: Regimen Cycle Patients n FN Events n (%) Grade 3 Neutropenia Events n (%) Grade 4 Neutropenia Events n (%) NHL: Bendamustine ± rituximab Overall 307 22 (7.2) 13 (4.2) 54 (17.6) 1 307 12 (3.9) 5 (1.6) 28 (9.1) 2 225 3 (1.3) 4 (1.8) 21 (9.3) 3 173 2 (1.2) 4 (2.3) 15 (8.7) 4 130 2 (1.5) 4 (3.1) 10 (7.7) 5 92 4 (4.4) 4 (4.4) 8 (8.7) 6 69 2 (2.9) 2 (2.9) 0 (0) BC: TCH Overall 462 112 (24.2) 49 (10.6) 206 (44.6) 1 462 70 (15.2) 39 (8.4) 138 (29.9) 2 326 13 (4.0) 15 (4.6) 42 (12.9) 3 282 17 (6.0) 9 (3.2) 39 (13.8) 4 247 6 (2.4) 8 (3.2) 31 (12.6) 5 199 4 (2.0) 6 (3.0) 25 (12.6) 6 169 8 (4.7) 3 (1.8) 12 (7.1) BC: TC Overall 859 176 (20.5) 82 (9.5) 322 (37.5) 1 859 126 (14.7) 51 (5.9) 266 (30.9) 2 649 21 (3.2) 42 (6.5) 82 (12.6) 3 571 19 (3.3) 23 (4.0) 62 (10.9) 4 511 14 (2.7) 22 (4.3) 45 (8.8) 5 94 1 (1.1) 3 (3.2) 9 (9.6) 6 84 2 (2.4) 1 (1.2) 2 (2.4) MM: Lenalidomide / dexamethasone Overall 186 7 (3.8) 11 (5.9) 34 (18.3) 1 186 2 (1.1) 8 (4.3) 17 (9.1) 2 101 3 (3.0) 5 (5.0) 14 (13.9) 3 63 2 (3.2) 2 (3.2) 8 (12.7) 4 37 0 (0) 0 (0) 4 (10.8) Disclosures Family: Amgen Inc.: Research Funding. Klippel:Amgen Inc.: Employment, Equity Ownership. Li:Amgen Inc.: Employment, Equity Ownership. Page:Amgen Inc.: Employment, Equity Ownership.
42
Getz, Kayla R., Myung Sik Jeon, Lili Liu, Lei Liu, Chongliang Luo, Jingqin Luo, and Adetunji T. Toriola. "Abstract 3429: Using metabolomics to identify biomarkers mediating the associations of adiposity in childhood and early adulthood with mammographic breast density in premenopausal women." Cancer Research 84, no. 6_Supplement (March 22, 2024): 3429. http://dx.doi.org/10.1158/1538-7445.am2024-3429.
Анотація:
Abstract Introduction: Mammographic breast density (MBD), a strong predictor of breast cancer risk, is highly influenced by body mass index (BMI) in childhood and early adulthood, but the mechanisms elucidating this relationship are undetermined. To our knowledge, no study has explored the mediating role of biomarkers on the relationship between early-life adiposity and MBD. The goal of this study is to discover metabolites that mediate the relationship between BMI at ages 10 and 18 with MBD in premenopausal women. Methods: This study includes premenopausal women who had their screening mammogram at Washington University in St. Louis, MO, and provided a fasting blood sample. Metabolon performed untargeted metabolomic profiling, detecting 1,074 metabolites. Metabolites missing >300 observations were excluded, leaving 828 metabolites; the other missing values were imputed using the nearest neighbor method. To mitigate batch effect, we normalized the metabolite peak area data using ComBat. Volumetric percent density (VPD) was calculated in 700 women using Volpara software. BMI at age 10 was estimated using the Stunkard pictogram, and BMI at age 18 was calculated from self-reported weight at 18 and height at study initiation. To assess the mediating role of the 828 metabolites, we performed high dimensional mediation analysis using the hima R package adjusting for potential confounders. Missing values in the covariates and BMI measures included in the mediation analysis were imputed using multivariate imputation by chain equations. Associations were considered significant if FDR p-value <0.1. Results: Four metabolites (glutamate, beta-cryptoxanthin, phytanate, and cortolone glucuronide (1)) mediated the relationship between BMI at age 10 and VPD; and 2 metabolites (glutamate, beta-cryptoxanthin) mediated the relationship between BMI at age 18 and VPD. Glutamate and beta-cryptoxanthin significantly mediated the relationship between both BMI measures and VPD, but glutamate was the strongest mediator across both time points. Glutamate mediated 6.7% (FDR p-value=0.06) and 9.3% (FDR p-value=0.008) of the total effect between BMI at age 10 and 18, respectively, on VPD. Beta-cryptoxanthin mediated 4.1% (FDR p-value=0.06) and 6.3% (FDR p-value=0.04), of the total effect between BMI at age 10 and 18, respectively, on VPD. Additionally, phytanate mediated 2.6% (FDR p-value=0.06) and cortolone glucuronide (1) mediated 2.0% (FDR p-value=0.07) of the total effect between BMI at age 10 and VPD. Conclusion: Amino acid, lipid, cofactor/vitamin, and xenobiotic metabolites mediated the associations of BMI in early-life and VPD in premenopausal women. This innovative study offers insight into the biological mechanisms underlying the link between early-life adiposity and MBD, which can support future research into breast cancer prevention. Citation Format: Kayla R. Getz, Myung Sik Jeon, Lili Liu, Lei Liu, Chongliang Luo, Jingqin Luo, Adetunji T. Toriola. Using metabolomics to identify biomarkers mediating the associations of adiposity in childhood and early adulthood with mammographic breast density in premenopausal women [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3429.
43
van Dijk, B., Y. Dakkak, D. Krijbolder, J. van Zeben, I. Tchetverikov, M. Reijnierse, and A. van der Helm-van Mil. "OP0290 WHICH INFLAMED TISSUES EXPLAIN A POSITIVE SQUEEZE TEST OF THE METATARSOPHALANGEAL JOINTS? A LARGE IMAGING STUDY TO INCREASE UNDERSTANDING OF A COMMONLY PERFORMED DIAGNOSTIC PROCEDURE." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 192.1–193. http://dx.doi.org/10.1136/annrheumdis-2022-eular.340.
Анотація:
BackgroundThe squeeze test of metatarsophalangeal (MTP-)joints is frequently used, because it is easy and cheap, and is traditionally perceived as a test for synovitis. Besides classic intra-articular synovitis also tenosynovitis and intermetatarsal bursitis (IMB) represent synovial inflammation, albeit juxta-articularly located. Both are frequently present in RA and occasionally in other arthritides. However, the contribution of IMB to MTP squeeze test positivity is unknown and the contribution of tenosynovitis has only been partially studied.ObjectivesTo assess whether tenosynovitis and IMB contribute to a positive MTP squeeze test.Methods192 early arthritis patients and 693 CSA-patients underwent the MTP squeeze test and forefoot MRI at first presentation. MRI measurements in age-matched healthy controls were used to define positivity for synovitis, tenosynovitis and IMB. Logistic regression was used; multivariable models adjusted for sex and simultaneous presence of inflammation features.ResultsIn early arthritis patients synovitis (OR 4.8 (95%CI 2.5–9.5)), tenosynovitis (2.4 (1.2–4.7)) and IMB (1.7 (1.2–2.6)) associated with positivity of the MTP squeeze test. Synovitis (3.2 (1.4–7.2)) and IMB (3.9 (1.7–8.8)) remained associated in multivariable analyses. Of patients with a positive MTP squeeze test, 79% had synovitis or IMB: 12% synovitis, 15% IMB and 52% both synovitis and IMB. In CSA-patients, subclinical synovitis (3.0 (2.0–4.7)), tenosynovitis (2.7 (1.6–4.6)) and IMB (1.7 (1.2–2.6)) associated with MTP squeeze test positivity. In multivariable analyses, synovitis remained independently associated (2.5 (1.5-4.1)) whilst tenosynovitis (1.5 (0.8-2.9)) and IMB did not (1.2 (0.8-1.8)). Of patients with a positive MTP squeeze test, 39% had synovitis or IMB: 10% synovitis, 15% IMB and 13% both synovitis and IMB.ConclusionBesides synovitis, also IMB contributes to pain upon compression in early arthritis, presumably due to its location between MTP joints. This is the first evidence showing that a positive MTP squeeze test positivity is not only explained by intra- but also juxta-articular inflammation.Disclosure of InterestsNone declared
44
De Paepe, Katja, Lawrence Bonne, Nicos Fotiadis, Naureen Starling, Ian Chau, Marco Gerlinger, Sheela Rao, et al. "Complications and seeding risk after percutaneous liver biopsy in an oncological setting." Journal of Clinical Oncology 36, no. 4_suppl (February 1, 2018): 246. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.246.
Анотація:
246 Background: Percutaneous biopsy of suspected liver metastases is a common practice for diagnostic purposes. Particularly, in the setting of oncological clinical trials, it is a relatively non-invasive method to obtain sufficient tissue for molecular analyses at regular set time points. However, various complications may occur, including seeding of the tumour along the biopsy tract. Only few reports exist on the actual incidence of seeding, on a limited number of tumor types. The aim of this study was to evaluate the technique’s safety and risk of seeding. Methods: All patients with an ultrasound or CT-guided liver biopsy between 2012-2016 were included. Medical records were reviewed retrospectively for post-biopsy complications and all follow-up imaging was re-assessed for the presence of seeding, defined as tumoral deposits in the biopsy needle tract. Results: In total 782 biopsies were performed in 550 patients (282 women, 268 men; mean age of 61 years), 43.9% (343/782) for trials and 56.1% (439/782) for diagnostic/molecular purposes, 93.7% (733/782) were diagnostic, revealing malignancy in 96.9% (710/733). Number of biopsies per patient ranged between 1 (n=387) to 7 (n=1), a co-axial system was used in 70.6% (552/782) and multiple passes in 29.4% (230/782). Complications were reported in 8.8% (69/782), more often pain (4.7%) and hypotension/vasovagal (2.3%). Admission and/or re-intervention were needed for more severe complications as bleeding (1.0%), sepsis/fever (1.1%), pulmonary embolism (0.3%) and pneumothorax (0.4%). Seeding was seen in 1.1% (8/782) of cases (2/44 melanoma, 1/11 GIST, 1/39 cholangiocarcinoma, 1/247 colorectal, 1/14 oesophagus, 1/97 breast, 1/31 prostate). Mean time for seeding was 208 days (range 43-469 d); mean post-biopsy survival time was 495 days in the seeding and 349 days in the non-seeding group. Conclusions: Percutaneous liver biopsy is a highly effective and safe method for tissue collection, with only a minimal risk of seeding.
45
Skrypnykov, P. M., T. P. Skrypnikova, N. A. Lupatsa, N. V. Raskolupa, G. Y. Ostrovska, V. I. Titarenko, and Y. O. Shkurenko. "ORAL HEALTH STATUS OF INTERNALLY DISPLACED PERSONS." Ukrainian Dental Almanac, no. 1 (March 23, 2023): 12–16. http://dx.doi.org/10.31718/2409-0255.1.2023.02.
Анотація:
Diseases of the oral cavity organs and tissues are an urgent medical problem. The urgency of the problem has been exacerbated by the extreme conditions in Ukraine in recent years: the COVID-19 pandemic and the war. These factors lead to stress, changes in living standards and living conditions, which leads to exacerbation of chronic diseases, and also impede the receipt of full, qualified medical care.
The Ministry of Health of Ukraine presents the regulatory framework "Rights and Obligations of Internally Displaced Persons", which guarantees medical examinations and treatment. According to the MoH order, the Poltava Regional Centre of Dentistry Dental Clinical Polyclinic has created conditions to provide dental care to IDPs at present.
Ways of implementation:
provision of dental care to patients by dentists of the polyclinic;
providing emergency dental care around the clock;
providing consultative and medical care by teachers of dental departments and doctors-interns.
The study analysed the condition of the oral cavity organs (teeth, periodontium, oral mucosa) of internally displaced persons and identified possible ways to preserve and restore dental health through preventive work, therapeutic, surgical and orthopaedic care.
The study analysed the work of dentists and teachers of dental departments in providing assistance to internally displaced persons over the 7 months of war in Ukraine. A total of 7388 people sought help. To assess the condition of the tissues and organs of the oral cavity, examinations were carried out using clinical, radiological and laboratory methods. If necessary, patients were consulted by related specialists.
It was found that in all examined patients, the caries prevalence rate was 100%, and the CPV index was equivalent in patients of the main group (19±1.27) and the control group (18±2.45). The number of patients with pulpitis was 2268 (37%) (acute, chronic pulpitis and exacerbation of chronic pulpitis).
Acute and exacerbation of chronic periodontitis was treated in 1852 patients (22.7%), periostitis in 855 (14%), and odontogenic maxillary sinusitis in 196 (3.2%).
Out of the total number of patients, 263 (4.26%) sought treatment for exacerbation of gingivitis, 482 (7.82%) for exacerbation of periodontitis, and 698 (11.4%) for diseases of the oral mucosa.
A high degree of reliability of exacerbation of periodontal and oral mucosa diseases was found in comparison with the control group.
46
Guz, Mykola, та Volodymyr Geval. "Посівні якості насіння найпоширеніших у західному регіоні України видів гіркокаштанів". Наукові праці Лісівничої академії наук України, № 17 (25 жовтня 2018): 61–71. http://dx.doi.org/10.15421/411821.
Анотація:
У зелених насадженнях різних видів і типів західного регіону України найпоширенішими є чотири види гіркокаштанів: Aesculus hippocastanum L., Aesculus pavіa L., Aesculus octаndra Marsh та Aesculus carnea Hayne. Для цих видів гіркокаштанів здійснено комплекс досліджень з визначення посівних якостей насіння – чистоти, доброякісності, вологості, маси 1000 насінин, технічної і ґрунтової схожості, енергії проростання та посівної придатності. Насінню досліджуваних видів гіркокаштанів властиві високий рівень чистоти (94,4-96,7%) і доброякісності (83,0-97%) та значна варіабельність середньої маси 1000 шт. насінин (8,8-20,2 кг). Найвищим рівнем технічної схожості, незалежно від типу субстрату, вирізняється насіння A. pavіa (78,0-87,0%), найменшим – A. carnea (52,0-60,0%).
Досліджено динаміку доброякісності та технічної схожості насіння впродовж 2000-2017 рр. Для видів A. pavіa, A. octаndra та A. carnea такі дослідження здійснено вперше.
У лісових і декоративних розсадниках рекомендовано використовувати уточнену норму висівання насіння A. hippocastanum: 375-400 г/м для осінньої і 430-460 г/м – для весняної сівби. Вперше обґрунтовано норму висівання насіння для трьох видів гіркокаштанів (A. оctаndra, A.pavіa, A. carnea ) для осінньої і весняної сівби, відповідно, 340-400 та 400-460 г/м; 220-265 і 250-300 г/м; 600-700 і 690-800 г/м посівного рядка.
47
Möller Parry, Maurício, Maristela Marques da Silva, Iracirema Silva Sena, and Francisco Plácido Magalhães Oliveira. "COMPOSIÇÃO FLORÍSTICA DA ARBORIZAÇÃO DA CIDADE DE ALTAMIRA, PARÁ." Revista da Sociedade Brasileira de Arborização Urbana 7, no. 1 (May 1, 2019): 143. http://dx.doi.org/10.5380/revsbau.v7i1.66550.
Анотація:
Foi realizado em 2010, um inventário da arborização da cidade de Altamira, Pará. Foram amostradas todas as vias públicas dos 25 bairros, com a utilização de uma planilha estruturada para a realização do censo total das espécies presentes nas vias. Foram identificadas 4.294 plantas de 120 espécies, de 105 gêneros e distribuídas em 40 famílias botânicas. A espécie mais frequente foi o ficus (Ficus benjamina), com um total de 1.062 espécimes que representaram 24,7% das árvores da cidade. A segunda espécie mais frequente foi o macharimbé (Cenostigma macrophyllum) com 793 espécimes (18,5% do total). Também aparecem a mangueira (Mangifera indica) com 376 espécimes (8,8%), o jambeiro (Syzygium malaccense) com 345 espécimes (8,0%), a palmeira imperial (Roystonea oleracea (Jacq.) O. F. Cook) com 135 espécimes (3,1%), a murta (Murraya paniculata), com 103 espécimes (2,4%) e o cajueiro (Anacardium occidentale) com 85 espécimes (2,0%). As famílias que apresentaram maior número de espécies foram a Fabaceae com 27 espécies, a Arecaceae com 10, Anacardiaceae com 6 e as famílias Malvaceae, Myrtaceae, Moraceae e Bignoniaceae apresentaram cada uma delas, 5 espécies. A grande diversidade de espécies encontradas resulta da participação efetiva da população na arborização da cidade de Altamira.
48
Supadmana Muda, Nur Rachman. "Implementation of Seismic Sensor to Detect Tank." Journal of World Science 3, no. 2 (February 29, 2024): 202–7. http://dx.doi.org/10.58344/jws.v3i2.557.
Анотація:
This study aims to investigate seismic sensors in detecting ground vibrations caused by tank or military vehicle movements. Ground vibrations generated by tank movements have specific characteristics, where the produced frequency remains constant depending on the tank's weight and the area of the track's footprint. The amplitude of these vibrations provides information about the detection range, wherein the larger the amplitude, the closer the detection range to the tank. The method employed involves field experiments or the collection of quantitative data from field trials. Test results indicate that ground vibrations produced by tanks have an average frequency of 332 Hz, depending on the tank's weight and the area of the track's footprint. The average amplitude is 4.3 volts at a detection range of 1000 meters, 5.1 volts at 500 meters, 7.6 volts at 200 meters, 8.8 volts at 100 meters, and 12.1 volts at 50 meters. The implication of this research is that seismic sensors can be effectively used as tools to detect tank or military vehicle movements at different distances. These findings could be beneficial in the development of security systems or early detection in areas vulnerable to potential threats from tanks or military vehicles.
49
Chowdhary, Mudit, Akansha Chowdhary, Neilayan Sen, Nicholas George Zaorsky, Kirtesh R. Patel, and Dian Wang. "Does the addition of chemotherapy to neoadjuvant radiotherapy impact survival in high-risk extremity and trunk soft tissue sarcoma?" Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 11054. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.11054.
Анотація:
11054 Background: Large, high-grade extremity/trunk (ET) non-rhabdomyosarcoma soft-tissue sarcoma (STS) is at high risk for distant recurrence and death. The integration of chemotherapy (C) to standard of care neoadjuvant radiotherapy (RT) remains controversial, even for these patients. This study examines the impact of adding C to neoadjuvant RT on overall survival (OS) in high risk ET-STS. Methods: The National Cancer Data Base (NCDB) was queried for patients ≥18 years with high risk (≥5 cm + high grade) non-rhabdomyosarcoma ET-STS (WHO histology) who received neoadjuvant RT and limb sparing surgery from 2006-2014. Patients were next stratified based upon receipt of C (RT and CRT cohorts). Overall survival (OS) for RT vs CRT cohorts was analyzed using the Kaplan-Meier (KM) method, log-rank test, and Cox proportional hazards models. Propensity score-matched analysis (PSM) was employed to account for potential treatment selection bias between cohorts. Results: A total of 848 (71.1%) and 344 (28.9%) patients received RT and CRT, respectively. Patient cohorts were well-balanced except for the CRT cohort having higher rates of treatment in the West (22.1% vs 10.6%) & Midwest (28.3% vs 22.7%), Charlson-Deyo [CD] score 0 vs ≥1 (85.5% vs 79.4%), younger age (≤50) (45.9% vs 21.7%), synovial sarcoma histology (18.9% vs 3.2%), earlier year of diagnosis (2006-2010) (39.5% vs 32.3%), and positive lymphovascular invasion (2.0 vs 1.51%), (p < 0.05 each). The KM 5-year OS was significantly higher in the CRT vs RT cohort: 69.2% vs 58.1% on univariate (p < 0.0001) and multivariate analysis (Hazard Ratio [HR]: 0.66; 95% Confidence Interval [CI]: 0.52-0.85; p = 0.001) even after adjusting for age, race, income, CD score, histology, tumor size, tumor grade, and primary site (lower extremity; upper extremity; trunk). PSM identified evenly matched cohorts of 300 patients each with respect to age, income, CD score, histology, grade, tumor size, and primary site. The addition of neoadjuvant C remained prognostic for OS on PSM (HR: 0.74 [0.56-0.99], p = 0.042). Conclusions: The addition of C to neoadjuvant RT was associated with improved OS in patients with high risk non-rhabdomyosarcoma ET-STS in the NCDB. These hypothesis generating results support prospective evaluation.
50
Mellor, Rebecca, Kim Bennell, Alison Grimaldi, Philippa Nicolson, Jessica Kasza, Paul Hodges, Henry Wajswelner, and Bill Vicenzino. "Education plus exercise versus corticosteroid injection use versus a wait and see approach on global outcome and pain from gluteal tendinopathy: prospective, single blinded, randomised clinical trial." British Journal of Sports Medicine 52, no. 22 (November 2018): 1464–72. http://dx.doi.org/10.1136/bjsports-2018-k1662rep.
Анотація:
ObjectiveTo compare the effects of a programme of load management education plus exercise, corticosteroid injection use, and no treatment on pain and global improvement in individuals with gluteal tendinopathy.DesignProspective, three arm, single blinded, randomised clinical trial.SettingBrisbane and Melbourne, Australia.ParticipantsIndividuals aged 35–70 years, with lateral hip pain for more than 3 months, at least 4/10 on the pain numerical rating scale, and gluteal tendinopathy confirmed by clinical diagnosis and MRI; and with no corticosteroid injection use in previous 12 months, current physiotherapy, total hip replacement, or neurological conditions.InterventionsA physiotherapy led education and exercise programme of 14 sessions over 8 weeks (EDX; n=69), one corticosteroid injection (CSI; n=66), and a wait and see approach (WS; n=69).Main outcomesPrimary outcomes were patient reported global rating of change in hip condition (on an 11 point scale, dichotomised to success and non-success) and pain intensity in the past week (0=no pain, 10=worst pain) at 8 weeks, with longer term follow-up at 52 weeks.ResultsOf 204 randomised participants (including 167 women; mean age 54.8 years (SD 8.8)), 189 (92.6%) completed 52 week follow-up. Success on the global rating of change was reported at 8 weeks by 51/66 EDX, 38/65 CSI, and 20/68 WS participants. EDX and CSI had better global improvement scores than WS (risk difference 49.1% (95% CI 34.6% to 63.5%), number needed to treat 2.0 (95% CI 1.6 to 2.9); 29.2% (13.2% to 45.2%), 3.4 (2.2 to 7.6); respectively). EDX had better global improvement scores than CSI (19.9% (4.7% to 35.0%); 5.0 (2.9 to 21.1)). At 8 weeks, reported pain on the numerical rating scale was mean score 1.5 (SD 1.5) for EDX, 2.7 (2.4) for CSI, and 3.8 (2.0) for WS. EDX and CSI participants reported less pain than WS (mean difference −2.2 (95% CI −2.89 to −1.54); −1.2 (−1.85 to −0.50); respectively), and EDX participants reported less pain than CSI (−1.04 (−1.72 to −0.37)). Success on the global rating of change was reported at 52 weeks by 51/65 EDX, 36/63 CSI, and 31/60 WS participants; EDX was better than CSI (20.4% (4.9% to 35.9%); 4.9 (2.8 to 20.6)) and WS (26.8% (11.3% to 42.3%); 3.7 (2.4 to 8.8)). Reported pain at 52 weeks was 2.1 (2.2) for EDX, 2.3 (1.9) for CSI, and 3.2 (2.6) for WS; EDX did not differ from CSI (−0.26 (−1.06 to 0.55)), but both treatments did better than WS (1.13 (−1.93 to −0.33); 0.87 (−1.68 to −0.07); respectively).ConclusionsFor gluteal tendinopathy, education plus exercise and corticosteroid injection use resulted in higher rates of patient reported global improvement and lower pain intensity than no treatment at eight weeks. Education plus exercise performed better than corticosteroid injection use. At 52 week follow-up, education plus exercise led to better global improvement than corticosteroid injection use, but no difference in pain intensity. These results support EDX as an effective management approach for gluteal tendinopathy.Trial registration numberProspectively registered at the Australian New Zealand Clinical Trials Registry (ACTRN12612001126808).